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Abstract 
 
 
Acyl-Coenzyme A: Isopenicillin N Acyl Transferase (AT) is a key enzyme in the 
biosynthesis of β-lactam antibiotics in penicillin producing organisms such as P. 
chrysogenum and A. nidulans.  Its natural activity is to exchange the side chain of the 
low activity antibiotic IPN [18] for the phenylacetyl side chain resulting in the more 
active antibiotic Penicillin G [5].  The biosynthesis of β-lactams has been exploited 
towards producing these compounds for therapeutic use.  However, increasing bacterial 
resistance means new analogues in this compound class are constantly sought. 
As well as improving current production methods of β-lactam antibiotics, AT’s broad 
substrate specificity means it could potentially play a role in the development and 
production of alternative β-lactam antibiotics that are able to overcome resistance. 
This thesis describes the identification of an AT mutant with improved acylation 
activity (AAT activity) via screening of an AT library using a previously developed 
screening method.  Approaches towards the development of a method for the 
identification of AT mutants with improved hydrolysis activity were also explored.  The 
main problem to overcome in developing such a screen is the inhibitory effect of 6-APA 
[1], the product of hydrolysis, on AT’s IAT activity.  The first approach investigated the 
potential of increasing the sensitivity of an assay by targeting AT to the periplasm.   A 
second approach using β-lactamases to hydrolyse 6-APA [1] thus freeing up the active 
site of AT was also investigated. 
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Preface 
 
 
Chapter one is a general introduction to the field of β-lactam antibiotics, followed by 
three results and discussion chapters.  Chapter two describes the search for AT mutants 
with improved AAT activity.  Chapters three and four describe two approaches towards 
the development of screening or selection methods for the identification of AT mutants 
with improved IAT activity; Chapter three using periplasmic expression of AT and 
Chapter four using a β-lactamase.  Chapters five and six contain information on the 
experimental methods used in this research.  Chapter five details the reagents and 
equipment used and Chapter six the general techniques employed. 
  
 8 
Declaration 
No portion of the work referred to in the thesis has been submitted in support of an 
application for another degree or qualification of this or any other university or other 
institute of learning. 
Copyright Statement 
i. The author of this thesis (including any appendices and/or schedules to this thesis) 
owns certain copyright or related rights in it (the “Copyright”) and s/he has given The 
University of Manchester certain rights to use such Copyright, including for 
administrative purposes. 
ii. Copies of this thesis, either in full or in extracts and whether in hard or electronic 
copy, may be made only in accordance with the Copyright, Designs and Patents Act 
1988 (as amended) and regulations issued under it or, where appropriate, in accordance 
with licensing agreements which the University has from time to time. This page must 
form part of any such copies made. 
iii. The ownership of certain Copyright, patents, designs, trade marks and other 
intellectual property (the “Intellectual Property”) and any reproductions of copyright 
works in the thesis, for example graphs and tables (“Reproductions”), which may be 
described in this thesis, may not be owned by the author and may be owned by third 
parties. Such Intellectual Property and Reproductions cannot and must not be made 
available for use without the prior written permission of the owner(s) of the relevant 
Intellectual Property and/or Reproductions. 
iv. Further information on the conditions under which disclosure, publication and 
commercialisation of this thesis, the Copyright and any Intellectual Property and/or 
Reproductions described in it may take place is available in the University IP Policy
 (see http://documents.manchester.ac.uk/DocuInfo.aspx?DocID=487), 
in any relevant Thesis restriction declarations deposited in the University Library, The 
University Library’s regulations 
 (see http://www.manchester.ac.uk/library/aboutus/regulations) 
and in The University’s policy on Presentation of Theses.
 9 
Acknowledgements 
 
 
I would like to thank Professor John Sutherland for his expert supervision and for 
giving me the opportunity to work with him.  His encyclopaedic knowledge of both 
chemistry and biology was awe inspriring.  Thanks also go to DSM for funding this 
research. 
I would like to thank the administrative and technical staff at the university, in particular 
Paul Fullwood in the School of Biological Sciences (Stopford Building), who was 
responsible for the DNA sequencing required for this project. 
I have to thank all the Sutherland group members, past and present.  Special mentions 
go to Basile, for quickly teaching me molecular biology before heading off to write his 
own thesis and for proof reading sections of this one.  Bea, also for proof reading but 
mainly for being a good friend throughout my PhD. Lello, Lee, Johnny, Jesus, Matt and 
Fabian for making my time in and out of the lab fun.  Andrew for always being an email 
away with advice. 
Last but by no means least, my parents without whose support and encouragement this 
would not have been possible. 
 10 
Abbreviations 
 
 
 
6-APA   6-aminopenicillanic acid 
7-ACA  7-aminocephalosporanic acid 
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AT   acyl-coenzyme A:isopenicillin N acyltransferase 
ATP   adenosine-5'-triphosphate 
ato   genes encoding acetyl-CoA:acetate CoA transferase 
bp   base pair 
BSA   bovine serum albumin 
C-   carboxy- 
cef   gene involved in cephalosporin biosynthesis 
cef D   gene encoding IPN epimerase 
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cef EF   gene encoding DAOCS/DACS 
cef F   gene encoding DACS 
cef G   gene encoding DAC acetyltransferase 
cam   chloramphenicol  
C. acremonium Cephalosporium acremonium 
CFE   cell-free extract 
CFU   colony forming unit 
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DAOC   deacetoxycephalosporin C 
DAOCG  deacetoxycephalosporin G 
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HPLC   high performance liquid chromatography 
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Symbols for Nucleic and Amino Acids 
 
Nucleic acids 
A adenine 
C cytosine 
G guanine 
T thymine 
N A, C, G or T. 
 
Amino acids 
Amino Acid Three Letter Code One Letter Code 
Alanine 
Cysteine 
Aspartic acid 
Glutamic acid 
Phenylalanine 
Glycine 
Histidine 
Isoleucine 
Lysine 
Leucine 
Methionine 
Asparagine 
Proline 
Glutamine 
Arginine 
Serine 
Threonine 
Valine 
Tryptophan 
Tyrosine 
Ala 
Cys 
Asp 
Glu 
Phe 
Gly 
His 
Ile 
Lys 
Leu 
Met 
Asn 
Pro 
Gln 
Arg 
Ser 
Thr 
Val 
Trp 
Tyr 
A 
C 
D 
E 
F 
G 
H 
I 
K 
L 
M 
N 
P 
Q 
R 
S 
T 
V 
W 
Y 
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The reasonable man adapts himself to the world; the unreasonable one persists in trying 
to adapt the world to himself.  Therefore all progress depends on the unreasonable man. 
 
G.B. Shaw 
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CHAPTER ONE 
Introduction 
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1.1 The Discovery and Development of β-Lactam Antibiotics 
β-lactam antibiotics are the most widely used chemotherapeutic compounds in use 
today and their discovery and development is one of the major advances of modern 
times.  Since their discovery mortality rates due to previously fatal bacterial infections 
have fallen, and without them the modern surgery that we now take for granted would 
not be possible. 
Penicillin was initially discovered in Oxford by Alexander Fleming in 1929 (Fleming 
1929) and he recognized its potential in the use of surgical dressings.  However, it was 
not until the early 1940’s that its in vivo antibacterial activity was demonstrated (Chain 
1940; Abraham 1941).  Subsequent development and mass production of Pencillin was 
achieved by collaborations between British and American research institutions and 
industry, largely driven by the need created by World War II (Abraham 1990).  These 
efforts were rewarded in 1945 with the Nobel Prize in Physiology or Medicine being 
awarded jointly to Sir Alexander Fleming, Ernst Boris Chain and Sir Howard Walter 
Florey "for the discovery of penicillin and its curative effect in various infectious 
diseases". 
In 1945 the structure of Penicillin was elucidated (Crowfoot 1948) and this information 
enabled the total synthesis of Penicillin which was achieved by 1950 (Sheehan and 
Henerylogan 1962).  However, this method was not suitable for the large-scale 
production of β-lactams. 
In 1957 the penicillin nucleus, 6-aminopenicillanic acid (6-APA) [1] was isolated from 
fermentation broths (Batchelor, Doyle et al. 1959) which allowed the production of 
semi-synthetic β-lactams and the first chemotheraupeutic semi-synthetic penicillin, 
Methicillin [2] was introduced in 1960 (Rolinson and Geddes 2007).  The widespread 
use and misuse of penicillins lead to the emergence of bacterial resistance and other 
semi-synthetic analogs were designed and developed in order to overcome this concern; 
this race against bacterial resistance still continues. 
Work towards the cephalosporin β-lactam antibiotics followed a similar path.  A 
cephalosporin producing strain was first discovered by Guiseppe Brotzu in 1945.  
Subsequent identification of Cephalosporin C [3] (Newton and Abraham 1954) 
followed.  However, the corresponding cephalosporin nucleus, 7-aminocephalosporanic 
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acid (7-ACA) [4] was not so easy to obtain by fermentation methods therefore semi-
synthetic analogues were not so forthcoming.  In 1961 Lilly Research labs developed a 
method of chemically expanding the five-membered ring in Penicillin G [5], the 
deacylation of which, lead to the cephalosporin nucleus (Morin, Roeske et al. 1962).  
The structure of Cephalosporin C [3] was elucidated and in 1964 the Nobel Prize in 
Chemistry was awarded to Dorothy Crowfoot Hodgkin "for her determinations by X-
ray techniques of the structures of important biochemical substances". 
The bulk production of β-lactam antibiotics is a marvelous example of biotechnology 
and as a result they are commodity chemicals unlike other pharmaceuticals.  However, 
increasing bacterial resistance means the continual development of these clinically vital 
compounds is essential if we are to enjoy our current standards of healthcare. 
1.2 β  -Lactam Antibiotic Classes 
There are many β-lactam antibiotics in use today.  Their common structural feature is 
the highly reactive four-membered β-lactam ring.  An ever-increasing class of 
compounds, classification is primarily based on their structures with further sub-
division based on their bacterial range of action.  They can be described in terms of a β-
lactam nucleus with a side chain.  Different combinations result in different properties 
for example amoxicillin [6] is orally stable whereas Penicillin G [5] is not. 
1.2.1 Penicillins 
Penicillins are β-lactams that contain 6-APA [1] as the β -lactam nucleus.  This consists 
of a five-membered thiazolidine ring fused to the four-membered β-lactam ring.  They 
are generally classified according to their range of action narrow- medium- broad or 
extended-spectrum.  Some examples are shown in Figure 1.1. 
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Figure 1.1 Examples of penicillins 
1.2.2 Cephalosporins 
Cephalosporins are β-lactams that contain either 7- aminocephalosporanic acid, 7-ACA 
[4] or 7-aminodeacetoxycephalosporanic acid, 7-ADCA [11] as the β -lactam nucleus.  
They differ to penicillins in that a six-membered dihydrothiazine ring is fused to the 
four-membered β-lactam ring.  They are generally classified by generations, which like 
the penicillins are based on their range of action and also their time of development.  
Some clinically useful examples are shown in Figure 1.2. 
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Figure 1.2 Examples of cephalosporins
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1.2.3 Other Classes of β-Lactams 
Other classes of β-lactams contain a similar fused five-membered ring like penicillins, 
however, in place of the sulfur there is a carbon (e.g. thienamycin [16]), an oxygen (e.g. 
clavulanate [17]) or no second ring at all i.e. monobactams.  (Shown in Figure 1.3). 
N
O COOH
O
S NH2
 
N
O
O COOH
COOH
 
thienamycin [16] clavulanate [17] 
Figure 1.3 Other classes of β-lactam antibiotics 
1.3 Mode of action  
How β-lactam antibiotics actually work in treating bacterial infections has been studied 
since the discovery of penicillin.  An understanding of their mechanism allows the 
design of more efficient, broad range antibiotics, the need for which is ever increasing 
as bacterial resistance continues apace. 
Initial clues as to how they might work came from the observation of various effects of 
Penicillin G on bacteria.  E. coli could be grown in the presence of Penicillin G [5] in 
hypertonic media.  The resulting protoplasts did not lyse in the medium but did lyse 
when transferred to water.  It was also observed that these protoplasts did not form 
when penicillin was present but the requirements for growth were not (Lederberg 1956).  
Penicillin was also found to only kill growing cells (Hurwitz, Reiner et al. 1958) and 
finally, Gram-negative bacteria are less susceptible to penicillin than Gram-positive 
bacteria. 
 It was later shown that penicillin interferes with a cross linking transpeptidation 
reaction during the last stage of bacterial cell wall formation and it was proposed that 
penicillin is an analogous substrate for the transpetidase enzyme responsible for this 
reaction (Tipper and Stroming.Jl 1965; Wise and Park 1965). 
The cell wall is made up of peptidoglycan, which consists of linear polysaccharide 
chains cross-linked by pentapeptides. The polysaccharide chains are made up of 
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alternating amino sugar units N-acetylglucosamine (GlcNAC) and N-acetylmuranic acid 
(MurNAC) linked via β-1, 4 linkages.  The pentapeptides are attached to the MurNAC 
sugar units and their amino acid sequence is usually, though not always, L-Ala-γ-D-Glu-
X-D-Ala-D-Ala where X is generally meso-diaminopimelate (m-DAP) in Gram-
negative bacteria and L-Lys in Gram-positive bacteria (Bugg and Walsh 1992) (Figure 
1.4). 
Cross-links between the polysaccharide chains are formed by transpeptidation reactions 
between the polypeptides attached to MurNAC.  At the terminus of these polypeptide 
chains are D-amino acids and it is these that penicillins are structurally analogous to. 
Penicillins inhibit transpeptidation by binding irreversibly to transpeptidases via a 
covalent bond formed between a serine residue on the enzyme and the carbonyl carbon 
of the β-lactam ring.  For this reason, these enzymes are also known as penicillin 
binding proteins (PBPs). 
 
Figure 1.4 Simplified structure of peptidoglycan (Bugg and Walsh 1992). 
The reduction in cross-linkages means that the cell wall is not as rigid and the cell 
succumbs to osmotic pressure and dies.  Fortunately there are no equivalent enzymes in 
human biosynthesis therefore penicillins specifically target bacteria, which is why they 
are so clinically useful. 
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1.4 Bacterial Resistance 
Although effective at inhibiting peptidoglycan biosynthesis in bacteria the widespread 
use and misuse of β-lactam antibiotics has allowed bacteria to evolve in order to 
overcome their effects.  There are four primary mechanisms by which bacteria can resist 
β-lactam antibiotics (Babic, Hujer et al. 2006; Drawz and Bonomo 2010) and these are 
detailed briefly below. 
1.4.1 Production of β-Lactamases 
This is the most common and important mechanism of resistance in Gram-negative 
bacteria.  β-lactamases, as their name suggests, inactivate β-lactam antibiotics by 
hydrolyzing the amide bond of the β-lactam ring (§ Scheme 1.1).  The first β-lactamase 
was observed around the same time as β-lactam antibiotics were themselves undergoing 
initial discovery and development (Abraham 1940). 
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Scheme 1.1 To show the hydrolysis of a β-lactam by a β-lactamase 
There are currently two approaches towards overcoming the resistance inferred to 
bacteria by constantly evolving β-lactamases.  One is the discovery and design of 
different β-lactam antibiotics that are not so readily hydrolysed by β-lactamases.  The 
other is the development of suitable β-lactamase inhibitors.  These compounds are also 
β-lactams and they inhibit by binding irreversibly to β-lactamases thus preventing them 
from hydrolyzing the β-lactam antibiotics they are used in conjunction with.  However, 
due to the rapid rate of β-lactamase evolution this is a constant challenge, made all the 
more difficult by their necessary exposure to a wide variety of chemical agents. 
The potential use of β-lactamases was investigated in this project and further discussion 
can be found in Chapter 4. 
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1.4.2 Changes in the Active Site of PBPs 
As discussed above (§ 1.3) PBPs (or transpeptidases) play a role in cell wall formation 
and are inhibited by irreversible binding of β-lactam antibiotics.  Changes in the active 
site lower the affinity for β-lactam antibiotics thus increasing resistance to these agents.  
Examples in pneumococci have been recorded (Laible, Spratt et al. 1991). 
1.4.3 Decreased Expression of Outer Membrane Proteins  
Outer membrane proteins in bacterial cell walls allow substances e.g. β-lactam 
antibiotics to permeate the cell therefore any changes in their expression or structure can 
lower their permeability.  However, this is usually not enough on its own to affect 
resistance and these mutants are often found in combination with β-lactamases 
(Doumith, Ellington et al. 2009). 
1.4.4 The Use of Efflux Pumps 
Efflux pumps are also proteins in the cell membrane and are capable of exporting 
substances from the cell.  In addition to altered cell permeability and β-lactamases they 
are another mechanism bacteria can evolve to improve their ability to resist β-lactam 
antibiotics. 
Despite the growing problem of resistance to β-lactam antibiotics they are still the drug 
of choice due to their low cost and low toxicity and their development continues.  
Current efforts focus on improving production methods and exploring the potential of 
alternative β-lactam antibiotics that can be created from various combinations of 
nucleus and side chains.  In order to develop alternative β-lactam antibiotics an 
understanding of how they are produced in organisms has been the subject of much 
study.  This information has made possible the manipulation of these organisms towards 
producing analogous compounds and optimizing production methods. 
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1.5 The Biosynthesis of β-Lactam Antibiotics 
1.5.1 The Biosynthetic Pathway 
The sulfur containing penicillins and cephalosporins are the focus of this work and their 
biosynthesis will be discussed.  Biosynthesis starts from the same amino acid precursors 
for both penicillins and cephalosporins. The initial steps in both routes are towards the 
synthesis of Isopenicillin N (IPN) [18] after which the routes for penicillins and 
cephalosporins then necessarily differ.  The details are discussed below (Martín 2010). 
The formation of IPN [18] is carried out in two steps starting from the three amino acids 
L-α-aminoadipic acid [19], L-cysteine [20] and L-valine [21] using 2 enzymes, ACV 
synthetase (ACVS) and IPN synthase (IPNS).  L-α-aminoadipic acid [19] is a non-
proteinogenic amino acid formed from lysine. 
ACVS takes the three amino acids, L-α-aminoadipic acid [19], L-cysteine [20] and L-
valine [21] and forms the tripeptide, L-δ-(α-aminoadipyl)-L-cysteinyl-D-valine (ACV) 
[22].  After initial activation of the amino acids with ATP, the resulting aminoacyl-
adenylates are bound to the enzyme as thioesters.  Valine is then epimerized from the L- 
to the D-isomer by ACVS.  The enzyme then links all three aminoacyl-adenylates to 
form ACV [22] which is then released via internal thioesterase activity (Martin 2000).  
ACV synthetases are multifunctional proteins as demonstrated by this sequence of 
events.  They are encoded by the pcbAB gene, which occurs in fungal and bacterial 
penicillin and cephalosporin gene clusters. 
The next step in the pathway is carried out by IPNS.  IPNS takes the tripeptide ACV 
[22] and removes four protons, subsequent cyclisation to form the penam nucleus 
results in the formation of IPN [18], itself weakly antibiotic.  IPNS is encoded by the 
pcbC gene. 
Once IPN [18] is formed it is here that the pathways for penicillins and cephalosporins 
diverge. 
For the biosynthesis of penicillins, the next and final step after IPN [18] formation is 
carried out by an acyltransferase (AT) encoded by the penDE gene.  Hydrolysis of the 
α-aminoadipoyl side chain of IPN [18] by the acyltransferase results in the formation of 
the penicillin nucleus, 6-APA [1], which is then re-acylated with an acyl-Co-A 
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derivative as acyl donor to give the corresponding penicillin.  For example acylation 
with phenylacetic acid gives Penicillin G [5].  The penDE gene is not present in 
cephalosporin producing organisms.  Acyltransferase (AT) is the subject of this study. 
Cephalosporin biosynthesis continues from IPN [18] as follows.  Epimerization of IPN 
[18] (L-isomer) to Penicillin N [23] (D-isomer) is carried out by an IPN epimerase 
encoded by two linked genes, cefD1 and cefD2.  The five-membered thiazolidine ring is 
then enzymatically expanded to the six-membered dihydrothiazine ring by 
deacetoxycephalosporin C (DAOC) synthase.  IPN [18] is a poor substrate for this 
enzyme, as are Penicillin G [5] and 6-APA [1].  However, adipyl- (Adi-Pen [26]) and 
glutaryl-6-APA [27] derivatives are accepted (Wu, Fan et al. 2005). 
The next step in the biosynthesis is hydroxylation at C-3 to form deacetylcephalosporin 
C (DAC) [25].  This can be done in two ways depending on the organism.  In A. 
chrysogenum DAOC synthase hydroxylates after chemical expansion of the ring.  
However, in bacteria there is a separate hydroxylase enzyme present encoded by the 
cefF gene. 
In C. acremonium the final step in the biosynthesis is carried out by DAC 
acyltransferase, encoded for by the cefG gene, which uses acetyl Co-A as an acetyl 
group donor; this results in the formation of Cephalosporin C [3]. 
In S. clavuligerus and N. lactamdurans, Cephalosporin C is not produced, as there is no 
DAC acyltransferase.  Instead, carbamoylation at C-3 and hydroxylation and 
methylation at C-7 results in Cephamycin C [28].  These reactions are carried out by a 
DAC-carbamoyl transferase, 7’-α-hydroxylase and methyltransferase enzymes encoded 
by cmcH, cmcI and cmcJ genes respectively (Martin, Gutierrez et al. 1994).  The overall 
route towards these compounds is shown in Scheme 1.2. 
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Scheme 1.2 To show the biosynthetic pathway of β-lactams 
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1.5.2 β-Lactam Biosynthetic Genes  
The genes involved in the biosynthesis of β-lactam antibiotics in various organisms 
have been extensively studied and reviewed. (Ingolia and Queener 1989; Martin, 
Gutierrez et al. 1994).  The nomenclature used is as follows; pcb corresponds to genes 
involved in the synthesis of penicillins and cephalosporins, pen indicates genes for 
penicillins only, cef for cephalosporins and cmc for cephamycins.  Many of the genes 
encoding enzymes involved in the biosynthesis of β-lactams have been cloned and 
sequenced towards the goal of further understanding the production of these 
compounds.  Importantly for this study, the penDE gene from both P. chrysogenum 
(Barredo, Vansolingen et al. 1989; Tobin, Fleming et al. 1990) and A. nidulans (Tobin, 
Fleming et al. 1990) have been determined.  A comparison of the corresponding amino 
acid sequences can be found in Appendix E. 
 
Figure 1.5 A) Penicillin gene clusters in P. chrysogenum and A. nidulans 
  B) Cephalosporin gene clusters in A. chrysogenum  
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1.5.3 β-Lactam Producing Organisms 
A variety of organisms produce β-lactam antibiotics.  Filamentous fungi are able to 
produce penicillins and cephalosporins but not clavams, carbapenams or monobactams.  
Bacteria make cephalosporins, cephamycins, clavams, carbapenams and monobactams 
but not penicillins.  This is summarized in Table 1.1 (Martin and Gutierrez 1995). 
Bacteria Class of β-lactam  Fungi 
Gram-negative Gram-Positive 
Aspergillus   
Penicillium   
Epidermophyton   
Trichophyton   
Polypaecilum   
Malbranchea   
Sartorya   
Penicillins 
Pleurophomopsis   
Cephalosporium Streptomyces Flavobacterium 
Anixiopsis Nocardia Xanthomonas 
Arachnomyces  Lysobacter 
Spiroidium   
Scopulariopsis   
Diheterospora   
Cephalosporins and 
Cephamycins 
Paecilomyces   
 Streptomyces  
 Streptomyces Serratia 
Clavams 
Carbapenams 
  Erwinia 
 Nocardia Pseudomonas 
  Gluconobacter 
  Chromobacter 
  Agrobacter 
Monobactams 
  Acetobacter 
Table 1.1 To show the β-lactams produced by various microorganisms  
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1.6 Acyl Coenzyme A: Isopenicillin N Acyltransferase (AT) 
1.6.1 Introduction 
As acyl coenzyme A: Isopenicillin N acyltransferase (AT) is the focus of this project, 
more detail on this enzyme is now provided. 
As has been discussed, AT catalyses the final step in the biosynthesis of Penicillin G [5] 
in P. chrysogenum and A. nidulans.  Penicillin G [5] may be formed by direct 
transacylation (IAT) of IPN [18] or by a two-step reaction involving amidohydrolase 
(IAH) and acyltransferase (AAT) activities with 6-APA [1] as the intermediate.  The α-
aminoadipic acid side chain of IPN [18] is exchanged for coenzyme A activated 
phenylacetic acid as shown in Scheme 1.3 (Alvarez, Cantoral et al. 1987; Whiteman, 
Abraham et al. 1990).  It can accept a wide variety of side chains, hydrophobic and 
hydrophilic acyl-CoA derivatives and some non CoA thioesters as acyl donors (Alonso, 
Bermejo et al. 1988; Ferrero, Reglero et al. 1991). 
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Scheme 1.3 To show the reactions catalysed by AT 
 
Mature AT is an α, β-heterodimeric protein containing 357 amino acids with 11kDa and 
29kDa subunits.  It is produced as an inactive 40kDa proenzyme precursor which is 
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autocatalytically activated by post translational cleavage of the peptide bond between 
Gly102 and Cys 103. 
1.6.2 Initial Identification and Characterisation 
Initial reports on the production of AT believed it to be a monomeric protein (Alvarez, 
Cantoral et al. 1987).  However further characterization studies showed it to be a 
40 kDa α,β-heterodimer, which undergoes post-translational cleavage of the Gly102-
Cys103 peptide bond resulting in α and β units of 11 and 29 kDa respectively. (Tobin, 
Fleming et al. 1990; Aplin, Baldwin et al. 1993; Aplin, Baldwin et al. 1993). Further 
investigations into the requirements for proenzyme cleavage into mature AT were done 
by introducing amino acid substitutions into the cleavage site, confirming the 
importance of Cys103 at the N-terminus of the 29kDa β-subunit for cleavage and 
activity (Tobin, Cole et al. 1995). 
It was found that both subunits are required for the production of active AT.  Co-
expression of plasmids encoding the α and β units in recombinant E. coli results in 
correctly folded active enzyme.  Expression of the units separately and subsequent 
mixing does not result in active AT; active AT is only achieved when the subunits are 
refolded in the presence of urea (Tobin, Baldwin et al. 1993). 
The development of a high level E. coli expression system for the penDE gene of P. 
chrysogenum (Aplin, Baldwin et al. 1993) and the resulting availability of recombinant 
AT has allowed its purification for mechanistic and structural studies. 
1.6.3 penDE gene 
The penDE gene from both P. chrysogenum (Barredo, Vansolingen et al. 1989; Tobin, 
Fleming et al. 1990) and A. nidulans (Tobin, Fleming et al. 1990) have been 
determined.  A comparison of the corresponding amino acid sequences can be found in 
Appendix E.  Entire genome sequencing of P. chrysogenum has also been carried out 
and a paralog of penDE was found.  However under the conditions employed for the 
study, the gene did not transcribe therefore its actual function was not revealed (van den 
Berg, Albang et al. 2008).  Further studies revealed this paralog Pc13g09140 to express 
a protein highly similar to AT.  However, no penicillin biosynthesis activity was 
detected even when targeted to the microbodies (Garcia-Estrada, Vaca et al. 2009). 
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1.6.4 Localization of AT to Microbodies 
The various steps in the biosynthesis of penicillins occur in different parts of the cell 
allowing each enzyme involved in the process to operate under its optimal conditions.  
It has been shown that AT is localized to the microbodies of P. chrysogenum and its 
location there is important for penicillin production.  Microbodies are small organelles 
(200-800 nm) surrounded by a single membrane.  Using site directed mutagenesis to 
remove the signal sequence (AlaArgLeu) required for targeting the protein to the 
microbodies, it was shown that although active AT was produced only IPN [18] was 
synthesized and not Penicillin G [5] (Muller, Bovenberg et al. 1992).  It has also been 
observed that high penicillin producing strains have a high volume of microbodies 
present (van den Berg, Albang et al. 2008).  However, in A. nidulans it has been shown 
that localization of AT in the peroxisomes is not essential for penicillin production 
(Sprote, Brakhage et al. 2009).  These differences between P. chrysogenum and A. 
nidulans are important to be aware of as A. nidulans is generally used as a model 
organism and P. chrysogenum for production.  It has been pointed out that β oxidation 
take place in the microbodies, the products of which are aliphatic CoA adducts, 
substrates for AT (Bokhove, Yoshida et al. 2010). 
 
 
Figure 1.6 Compartmentalization of the penicillin biosynthetic pathway. 1) ACV 
  synthetase; 2) IPN synthase; 3) AT; 4) Phenylacetyl-CoA ligase (Martín 
2010). 
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1.6.5 Structural Determination of AT 
To understand how AT catalyzes the acyltransferase reaction and recognizes various 
substrates its crystal structure is highly desirable.  Although recombinant technology 
has allowed the production of pure AT, obtaining pure homogenous preparations is 
difficult due to the propensity of the mature form to aggregate.  This in turn makes the 
preparation of crystals for study by x-ray difficult. 
However, this problem was circumvented with the use of the mutant Cys103Ala, which 
can be purified as a monodisperse protein in large yields.  This corresponds to the 
proenzyme form of the enzyme as autocatalytic cleavage between Gly102 and Cys103 
does not take place.  This proenzyme form of AT was purified and crystallized and was 
the first x-ray study on AT (Hensgens, Kroezinga et al. 2002). 
In another approach, the use of additives to prevent aggregation was investigated using 
dynamic light scattering (DLS).  It was found that incubation of purified AT with 5 mM 
DTT + 250 mM NaCl + 5 mM EDTA was effective in preventing aggregation.  AT was 
successfully crystallized and crystals diffracting up to 1.64Å resolution were obtained 
(Yoshida, Hensgens et al. 2005). 
Although the crystal structures of both the proenzyme (Cys103Ala mutant) and mature 
enzyme have been achieved, precise modelling of the substrate in the active site of AT 
has not been possible due to the difficulty in obtaining a substrate-AT complex for 
crystallographic studies.  However, a suggested substrate binding model based on the 
proenzyme Cys103Ala crystal structure has been proposed by this group and is 
discussed in Chapter 2 (§ 2.2). 
More recent modeling to further investigate the structure and functioning of AT by 
comparing the proenzyme (Cys103Ala mutant) and the mature enzyme has been carried 
out and is now discussed (Bokhove, Yoshida et al. 2010). 
AT belongs to the Ntn-hydrolase (N-terminal nucleophile aminohydrolases) 
superfamily.  Structures of this class have either serine, threonine or cysteine as the N-
terminal nucleophile and share similar folding patterns.  They consist of four layers of 
α-helices and β-sheets (αββα motif) and have equivalent stereochemistry at the active 
site.  In the case of AT cysteine is the N-terminal nucleophile and although it does not 
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show obvious sequence homology with other enzymes of this class, it does share the 
structural αββα motif. 
The residues required for autoproteolysis and catalysis were identified by comparing the 
precursor structure with a tetrahedral reaction intermediate model.  Interestingly the 
same residues are involved for both processes but they perform different roles. 
1.6.5.1 The Autoproteolysis Mechanism 
In order to obtain further insight into the mechanism of the autocatalytic cleavage of AT 
the residues around the cleavage site were investigated.  The structure of the proenzyme 
Cys103Ala mutant showed that the peptide bond between Gly102 and Cys103 was 
inaccessible to a protease or solvent indicating that activation is via an intramolecular 
catalytic event. 
Possible candidates to act as the nucleophile for such an event were considered.  A 
water molecule is present in the vicinity however the lack of a catalytic base to activate 
it eliminated this as a possibility.  Intramolecular attack by Cys103 was deemed more 
likely.  Cys103 is believed to be in the correct conformation due to the tight packing of 
the surrounding residues, allowing it to attack the scissile carbonyl bond.  Although in 
this case there is also no suitable base to activate the nucleophile, when the 
nucleophilicity of cysteine compared to serine or threonine was considered it was 
suggested that solvent would be sufficient to deprotonate Cys103 and indeed a suitable 
water channel was found to exist.  The resulting thiolate ion may then attack the 
carbonyl of Gly102. 
Collapse of the tetrahedral intermediate by protonation of the leaving group amine of 
Cys103 by a water molecule, results in a thioester intermediate, which is then attacked 
by the hydroxide ion to form a second tetrahedral intermediate.  Finally, this second 
tetrahedral intermediate collapses on protonation of the sulfur atom of Cys103 by 
another water molecule, which results in free C- and N- termini and overall cleavage of 
the Gly102-Cys103 peptide bond.  The backbone amide bond of Asp121 is in the 
correct position to stabilize the tetrahedral intermediates in both cases.  This sequence 
of events is shown in Scheme 1.4. 
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Scheme 1.4 To show the mechanism of autocatalytic cleavage of Gly102-Cys103 
1.6.5.2 Substrate Binding in AT and Mechanistic Implications 
In terms of identifying the active site and key residues for binding of substrates, AT was 
compared to enzymes that carry out similar reactions with similar substrates, namely 
cephalosporinase (CA) and Penicillin G acylase (PGA).  CA and PGA also belong to 
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the Ntn-hydrolase superfamily and like AT can cleave the side chains from β-lactams, 
7-ACA [4] in the case of CA and 6-APA [1] in the case of PGA. 
In the precursor mimic Cys103Ala, the active site is blocked by residues 95 through to 
102.  However, in the mature enzyme these residues were found to have moved, 
revealing a large binding site, much larger than that of CA or PGA.  Co-crystallisation 
of the mature enzyme with 6-APA [1] showed it to bind near Cys103.  Van der waals 
interaction of the thiazole ring with Phe122 and Phe123 was seen which correlated with 
the postulated binding proposed by this group discussed in Chapter 2 (§ 2.2).  A salt 
bridge between the carboxylate of 6-APA [1] and Arg310 was revealed. 
Co-crystallisation of IPN [18] was not possible.  However modeling based on the 
binding and coordination of Penicillin G in PGA led to a transition model resulting from 
nucleophilic attack of the sulfur atom of Cys103.  The key residues proposed are 
summarized in Table 1.2 below. 
Residues Comments 
Trp120 Undergoes conformational change in order to allow 
the α-aminoadipic acid side chain to bind. 
Lys154 H-bonding with carboxylate of α-aminoadipic acid. 
Gln118 H-bonding with amino of α-aminoadipic acid. 
Ala168 Forms part of oxyanion hole for carbonyl oxygen 
of scissile bond. 
Asn246 Forms part of oxyanion hole for carbonyl oxygen 
of scissile bond. 
Asp121 Transition state stabilization. 
Lys154, Tyr166, His182 Highly flexible residues which line the substrate 
binding site. 
Leu130, Ile146, Leu314, Phe315 Hydrophobic side chains in the active site exposed 
by rotation of Trp120. 
Thr126, Glu148 Hydrophilic side chains in the active site exposed 
by rotation of Trp120. 
Table 1.2 Summary of key residues identified by AT modeling 
Notable, is the presence of hydrophobic and hydrophilic residues in the active site 
which goes towards explaining how AT has such broad substrate specificity and can 
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accept such chemically diverse side chains such as the polar α-aminoadipic acid and the 
apolar phenylacetyl. 
It was also proposed that AT has a storage pocket for 6-APA [1]; 6-APA [1] relocates 
here to allow the α-aminoadipic acid side chain to leave the active site as shown in 
Figure 1.7.  This proposal is a further extension of the simple mechanism put forward 
by previous group member Darren Hart which proposed the idea of two binding 
pockets, one for the penicillin nucleus and one for the side chain (Hart 1996). 
 
Figure 1.7 To show the AT storage pocket of AT (Image kindly provided by Marcel 
  Bokhove). 
It was proposed that once IPN [18] has bound to the active site of AT, nucleophilic 
attack occurs at the amide bond between the penicillin nucleus and the α-aminoadipic 
acid side chain.  An α-aminoadipic acid-enzyme intermediate is formed and 6-APA [1] 
remains tightly bound in the penicillin nucleus binding pocket.  Hydrolysis of the acyl-
enzyme intermediate releases α-aminoadipic acid.  Phenylacetyl-CoA binds to the side 
chain binding pocket and phenylacylation of the enzyme takes place.  Nucleophilic 
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attack of the ester bond of the phenylacyl-enzyme intermediate by 6-APA [1] completes 
the formation of Penicillin G [5] which is released from the enzyme (§ Scheme 1.5). 
This mechanism was based on the kinetic information available at the time.  
Determination of the Km value for the three main activities of AT has been achieved 
however, since Michaelis constants depend on assay conditions such as pH and ionic 
strength the data cannot be compared directly between sources.  It is generally observed 
that AAT activity is much more efficient than IAT activity.  When IPN [18] is 
hydrolysed 6-APA [1] is bound to the active site of AT until it is converted into 
Penicillin G [5] in the presence of phenylacetyl-CoA.  The rate of this step slows down 
as the concentration of phenylacetyl-CoA [30] decreases, which suggests 6-APA [1] 
competitively inhibits the binding of IPN [18]. 
In summary, these findings particularly the broad substrate specificity of AT make it 
worthy of further investigation towards its potential exploitation for the improved 
production of β-lactam antibiotics. 
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Scheme 1.5 The proposed mechanism for IAT activity of AT (Hart 1996) 
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1.7 Project Aims 
The improved production of β-lactam antibiotics in use today and the development of 
new analogues for which resistance is not (yet) an issue are major goals of the 
pharmaceutical industry.  The aim of this project is to modify AT towards achieving 
these goals.  As has been discussed AT has a broad substrate specificity, which could be 
exploited and broadened further using directed evolution to meet the demand for new 
manufacturing routes preferably based on fermentation of final or late-stage 
intermediates particularly towards the production of cephalosporins. 
Although cephalosporins are generally regarded as better antibiotics due to their broader 
spectrum of activity and higher potency their use is limited by the cost and complexity 
involved in producing them.  Production of novel β-lactams is semi-synthetic in that the 
nucleus, either 6-APA [1], 7-ADCA [11] or 7-ACA [4] is obtained by fermentation 
methods then acylated with a chemically synthesized side chain.  For semi-synthetic 
cephalosporins, 7-ADCA [11] or 7-ACA [4] are required.  However obtaining these 
cephalosporin nuclei is difficult. 
Current manufacturing processes are based on fermentation of natural β-lactams which 
are then extracted from the fermentation mixture and the side chains cleaved 
enzymatically to obtain the β-lactam nucleus.  6-APA [1] owes its ease of production to 
two advantages in Penicillin G [5].  Firstly, the hydrophobic phenylacetyl side chain 
allows Penicillin G [5] to be easily extracted from the fermentation mixture with 
organic solvent.  Secondly, there are known acylases that are capable of cleaving this 
side chain thus giving 6-APA [1].  In the case of Cephalosporin C [3], the α-
aminoadipoyl side chain does not permit easy extraction from the fermentation for 
subsequent side chain cleavage. 
There are currently two routes towards the production of the cephalosporin nuclei 7-
ACA [4] and 7-ADCA [11].  7-ACA [4] can be obtained from the fermentation of high 
Cephalosporin C [3] producing strains.  The resulting fermentation broth is purified and 
the side chain is cleaved from Cephalosporin C [3] using an amidase to give 7-ACA [4] 
which is isolated by precipitation.  (Scheme 1.6).  Amidases used for the cleavage of the 
side chain are not efficient and the yields of 7-ACA [4] obtained are low.  Current work 
focuses on the development of efficient amidases. 
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7-ADCA [11] can be obtained from either Penicillin G or Penicillin V.  The penicillin is 
produced by fermentation and then the five-membered thiazolidine ring is expanded 
using either traditional chemical methods or increasingly, enzymatic methods from 
genetic engineering of the biosynthetic pathways.  Enzymatic cleavage of the side chain 
results in 7-ADCA [11].  (Scheme 1.7). 
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The method of chemical expansion is environmentally unfriendly therefore enzymatic 
methods have been developed.  Key breakthroughs in the engineering of biosynthetic 
pathways towards production of cephalosporins include the production of 
deacetoxycephalosporin C in recombinant P. chrysogenum containing the cefE gene 
from S. clavuligerus resulting in the enzymatic expansion of Penicillin N [23] 
(Cantwell, Beckmann et al. 1990). 
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Scheme 1.8 The production of cephalosporin intermediates via production of  
  adipoyl-cephalosporins in recombinant strains of Penicillium  
  chrysogenum (Crawford, Stepan et al. 1995)  
 
 43 
This idea was taken a step further and the use of P. chrysogenum strains containing 
either the expandase from S. clavuligerus or the expandase and hydroxylase from 
C.acremonium fed with adipic acid and subsequent cleavage of the fermentation 
product side chains gave 7-ADCA [11] and 7-ACA [4] respectively (Crawford, Stepan 
et al. 1995) (§ Scheme 1.8). 
These approaches can be improved using strain improvement methods and directed 
evolution techniques to increase the efficiency of the fermentation processes and the 
subsequent amidase cleavage reactions.  However, they do not get around the problem 
of extraction of the products from fermentation mixtures due to the presence of the 
aminoadipoyl and adipoyl side chains.   Extraction could be improved by the presence 
of a hydrophobic side chain such as the phenylacetyl side chain in Penicillin G [5]. 
This makes AT an obvious choice for improving the production of 7-ADCA [11] and 7-
ACA [4].  As well as improving its activity for the natural reaction and Penicillin G [5], 
its activity towards the adipoyl side chain towards the production of AdiPen [26] could 
also be improved.  Both Penicillin G [5] and AdiPen [26] are substrates for DAOCS the 
resulting expanded products can then be cleaved to give 7-ADCA [11] as shown in 
Scheme 1.9. 
There are advantages to both the routes shown in Scheme 1.9.  In the first route, 
although the first transacylation step by AT is not as efficient as the natural reaction of 
AT, the resulting AdiPen [26] is a much better substrate for the expandase enzyme .  In 
the case of route 2, the opposite is true; transacylation is efficient as it is the natural 
reaction of AT, however the subsequent ring expansion is not so easy. 
The second route is more preferable due to the presence of the hydrophobic 
phenylacetyl side chain, which would allow for more efficient extraction of the 
Cephalosporin G [31] product from the fermentation mixture. 
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Scheme 1.9 2 routes to 7-ADCA [11] using AT 
An even more ambitious approach would be to bypass both the transacylation of 6-APA 
[1] and subsequent ring expansion by using AT to directly transacylate Cephalosporin C 
[3] to produce Cephalosporin G [31], which could be easily extracted from fermentation 
mixtures and the side chain removed with an amidase to give 7-ADCA [11]. 
Although AT has demonstrated broad substrate specificity for the side chains of 
penicillins, this approach would require an AT variant with altered substrate specificity 
for the nucleus i.e. from penicillin nucleus 6-APA [1] to a cephalosporin nucleus, either 
7-ACA [4] or 7-ADCA [11].  Unpublished work from the group has shown that AT has 
 45 
low activity towards cephalosporin substrates (Tobin 1994) and a therefore more 
achievable goal of improving an existing activity rather than introducing a completely 
new one. 
This thesis describes the search for AT mutants with improved IAH and AAT activities 
which when further combined would lead to an overall improvement in AT transacylase 
activity (IAT).  Chapter 2 describes the use of an affinity screening method towards 
identifying AT mutants with improved AAT activity.  Chapters 3 and 4 describe work 
towards developing a screening method for the identification of AT mutants with 
improved IAT activity. 
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CHAPTER TWO 
Identification of AT Mutants with 
Improved AAT Activity 
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2.1 Introduction 
Previous work in the group had concentrated on the acylation activity of AT towards 
various substrates with considerable success.  The ultimate goal of the project is to 
modify AT with respect to cephalosporin substrates.  It had been observed (Tobin, 
1994) that AT has some activity, albeit low, with the cephalosporin nucleus, 7-ADCA 
[11].  So, instead of trying to introduce a new substrate specificity to AT ‘just’ an 
improvement on its natural activity was required.  To this end work began with a 
rational approach to improving AT’s acylation activity and altering its substrate 
specificity. 
2.2 A Rational Approach 
In order to rationally identify the important residues of an enzyme, crystallographic data 
is needed, ideally a substrate bound co-crystal structure.  Unfortunately, this data is not 
available for AT.  This is due to the difficulty of obtaining pure homogenous 
preparations of AT, as the pure enzyme is subject to severe aggregation.  However, this 
problem is overcome with the Cys103Ala mutant.  Although this mutant does not have 
the ability to be processed into the mature heterodimeric protein and therefore 
corresponds to the proenzyme form of AT, it can be purified in large yields allowing 
some crystallographic data to be obtained (Hensgens, Kroezinga et al. 2002).  This 
crystallographic data was used by the group to propose AT–IPN binding models, which 
led to the identification of key residues within the active site of AT that were subjected 
to further investigation. 
2.2.1 Proposed Key AT Residues 
A triad of residues, namely Arg89, Glu148 and Lys154, were believed to form part of a 
salt bridge with a carboxylate anion, initially that of IPN [18], later with that of 6-APA 
[1]. 
Hydrophobic interactions were thought possible between residues Thr90, Ala93, 
Phe122, Tyr166, and Ala168.  An edge-to-face interaction between Phe122 and Phe123 
was also believed to exist. 
Residues that were believed to be in and around the active site included, Arg89, Thr90, 
Glu91 and Ala93 of the α-subunit, and Cys103, Trp120, Phe123, Glu148, Lys154, 
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Tyr166, Ala168 and Ser181 of the β-subunit.  Residues Lys97 and His170 were also 
considered important due to their close proximity to the active site. 
A number of the residues, Leu35, Thr90, Tyr94, Ala93, Lys97, Phe122, Phe123, 
Tyr166, Ala168 and His170 were subjected to mutagenesis experiments, expressed and 
characterised by SDS-PAGE and their activities compared to that of wild type AT for 
various conversions as follows. 
2.2.2 Site Directed Mutagenesis of Key AT Residues 
The first residues to be investigated were Thr90 and Ala168 (Derome 2003) which were 
believed to be in the active site of AT.  It was rationalised that more room could be 
created in the active site of AT to accommodate larger cephalosporin nuclei by 
removing the methyl group from these residues by switching threonine for serine, and 
alanine for glycine.  It was anticipated that this would create enough space to alter 
substrate specificity while at the same time not alter main chain functions.  These 
mutants were made using site directed mutagenesis.  The resultant proteins were 
analysed by SDS-PAGE and seen to fold correctly.  The activity of the mutants, 
Thr90Ser and Ala168Gly, was compared to wild type AT by bioplate assay.  For the 
conversion of 6-APA [1] with PACoA [30] into Penicillin G [5], Thr90Ser had similar 
activity to wild type AT.  However, Ala168Gly had a much-reduced activity, which 
showed that it was indeed an important residue for AT activity.  For the conversion of 
O-carbamoyl-7-aminodeacetylcephalosporanic acid, OC-7-ADCA [29] with PACoA 
[30] into O-carbamoyldeacetylcephalosporin G, OCDAG [24], Ala168Gly again 
showed a decrease in activity compared to wild type AT.  However, Thr90Ser showed 
an increase of 5%.  These results validated the approach and other residues were 
investigated. 
Following on from the success of mutant Thr90Ser, Tyr166 was investigated (Cheung 
2006).  It is directly opposite Thr90 in the active site so the same strategy was applied, 
the creation of space by removing a functional group from the residue, in this case 
removal of the hydroxyl group by substituting tyrosine for phenylalanine.  This mutant 
did indeed show improved activity for OC-7-ADCA [29] and so the double mutant 
Thr90Ser Tyr166Phe was made with the aim of opening up the active site even more.  
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However, this proved a step too far as although this mutant did express correctly (as 
seen by SDS-PAGE), it showed no improvement in activity for OC-7-ADCA [29]. 
The edge-to-face interaction between Phe122 and Phe123 was also investigated with a 
series of site directed mutagenesis experiments (Cheung 2006).  It was considered 
important to conserve the hydrophobicity at these positions so substitutions were made 
for other hydrophobic residues, valine, leucine, isoleucine and methionine.  Proline was 
considered to be potentially too disruptive to the protein structure.  SDS-PAGE analysis 
revealed that substitution was not tolerated at position 122 as these proteins did not fold 
properly.  Although substitutions were tolerated at position 123 in terms of folding, 
none of the mutants showed any improvement in activity. 
Attention was then turned to residues in the outer layer of the active site.  At this time it 
was believed that the triad of residues, namely Arg89, Glu148 and Lys154, formed a 
salt bridge with the carboxylate anion of 6-APA [1], and not that of IPN [18] as 
originally supposed.  This led to the identification of other residues deemed worthy of 
investigation; Leu35, Tyr94, Lys97 and His170. 
Leu35 is located above the carboxylate anion of the IPN [18] side chain.  Substitutions 
at Leu35 were made to retain the hydrophobicity (valine, leucine, isoleucine and 
methionine).  Not all the substitutions were tolerated in terms of protein structure.  
However, of the mutants that did fold correctly, one, Leu35Met, did show some 
improvement in activity towards OCDAG [24] formation (Cheung 2006). 
Tyr94 points towards to the binding site of the enzyme.  The mutant Tyr94Phe was 
made in an attempt to again create more space in the active site.  Although there was no 
great improvement in activity, there was some activity despite partial proteolysis of the 
expressed protein (as seen by SDS-PAGE), which suggests that the hydroxyl group at 
this position was not essential (Cheung 2006). 
Lys97 was investigated due to its close proximity to Cys103 (Khara 2007).  Site 
saturation mutagenesis was carried out at this residue, which led to the identification of 
two interesting mutants and the suggestion that Lys97 was a ‘hotspot’.  Lys97Arg 
showed an increase in activity when compared to wild type AT for the conversion of 6-
APA [1] into Penicillin G [5].  Lys97Val showed an increased conversion of OC-7-
ADCA [29] into OCDAG [24].  Interestingly, the amino acid sequences for the penDE 
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gene from P. chrysogenum and A. nidulans differ in the same way at this point, i.e. a 
lysine residue at position 97 in P. chrysogenum and valine in A. nidulans. This led to a 
comparison of the genes from both organisms in the hope that by going from P. 
chrysogenum to A. nidulans cephalosporin activity would be favoured (§ Appendix E 
amino acid sequences for both organisms). 
The following mutants were made accordingly, Ala98Glu and Gln172His and 
investigated (Cheung 2006).  Both mutants showed an improvement in conversion of 
OC-7-ADCA [29] for the formation of OCDAG [24], unfortunately the double mutant, 
Ala98Glu Gln172His, did not. 
In summary, 5 useful mutants had been identified by the group, using a rational 
approach based on a putative binding model: Thr90Ser, Tyr166Phe, Leu35Met, 
Ala98Glu and Gln172His.  However, this number was too few for a round of DNA 
shuffling and in the absence of any new crystallographic data a random approach was 
needed in order to identify useful AT mutants.  As mutations at positions other than the 
active site and often far from, the active site can have a beneficial effect on enzyme 
activity but are impossible to predict, a random approach was employed. 
2.3 A Random Approach 
Random libraries were created via error prone PCR (epPCR) using Stratagene’s 
GeneMorph II Random Mutagenesis kit and methods to screen the libraries developed. 
Bioplate assay is really only suitable for analysing a handful of mutants at a time.  A 
screening or selection method was needed that would allow thousands of mutants to be 
analysed rapidly.  The use of an E. coli strain (E. coli ESS) that was sensitive to varying 
amounts of antibiotic was key to the methods developed in the group. 
2.3.1 High-Throughput Liquid Assay Screening and Results 
Initially a high throughput method was developed (Derome 2003).  This involved the 
use of a robotic colony picker to inoculate a 96-well micro titre plate (MTP).  Induction 
with IPTG followed by lysis with a commercially available reagent (BPER II) gave cell 
free extracts to which potassium clavulanate was added to inactivate any β-lactamase 
present, which would have interfered with the screen.  Substrates (OC-7-ADCA [29] 
and PACoA [30]) were added and the reactions incubated.  Aliquots of the resulting 
 51 
mixture were mixed with liquid media and added to a replica plate containing E. coli 
ESS.  Measuring the OD600 of the resulting solutions after a period of incubation 
allowed the amount of conversion to be determined by reference to an internal standard 
and the mutant responsible could be selected from the master plate for further analysis. 
A screen was carried out using this method albeit it smaller than originally planned due 
to the prohibitive cost of PACoA [30] - only 3000 mutants as opposed to the desired 
10000.  Although some potential ‘hits’ were isolated, upon further analysis these turned 
out to be false positives.  This was probably due to the fact that the library screened had 
only a low mutation rate (<50% of the clones contained mutation/s) making it difficult 
to pick out any useful mutants from such a high background of wild type AT especially 
when the number of colonies actually screened was smaller than desired. 
Although initially promising this screening method gave rise to a number of issues, 
which needed to be addressed if useful AT mutants were to be identified.  Firstly, 
library quality; a higher mutation library was needed.  Secondly, the prohibitive cost of 
PACoA [30] was limiting the size of screen that could be carried out.  Thirdly, the 
equipment used to carry out the screen was only available at our funding partners 
(DSM) laboratory in The Netherlands, a method that could be carried out in Manchester 
was highly desirable. 
2.3.2 Library Improvement 
The problem of library quality was solved by altering the parameters used during library 
creation with Stratagene’s GeneMorph II Random Mutagenesis kit, which led to the 
creation of a high mutation library (90% of the clones contained mutation/s) (Khara 
2007). 
2.3.3 Alternative Acyl Donor Substrates 
To address the issue of substrate cost, alternative substrates/analogues of PACoA [30] 
were sought.  Initially, a para-nitrophenyl ester [39] was considered with the possibility 
of exploiting the para-nitrophenoate ion [40] in a colorimetric assay (Figure 2.1).  
However, experimental determination of the rates of AT catalysed and uncatalysed 
hydrolysis of the para-nitrophenyl ester [39] found them to be too similar and the ester 
was deemed too hydrolytically labile to be useful.  Substituting the ester bond for the 
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stronger amide analogue would have reduced the rate of hydrolysis.  However, it would 
also have been structurally quite different from PACoA [30] and during the screening 
process would possibly lead to the selection of mutants that were not selective for 
PACoA [38] (Khara 2007). 
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Scheme 2.1 To show the formation of the para-nitrophenoate ion [40] 
Another alternative was sought and found with the use of N-acetyl cysteamine.  When 
considered more closely, the structure of PACoA [30] is a thioester made up of two 
parts; the acyl group carrier, coenzyme A, and the phenyl acyl component, which is 
transferred during acylation to the penicillin nucleus, 6-APA [1].  By using the thiol, N-
acetyl cysteamine, an analogous thioester acyl donor (PANAC [37]) was made which 
was a much cheaper, coenzyme A alternative.  This substrate was found to be utilised 
by AT and although it was not quite as good a substrate as the natural substrate, PACoA 
[30], it was good enough for screening purposes.  The only drawback was the 
possibility of obtaining ‘NAC’ selective mutants from the screen.  However, this was 
easily solved; any mutants found from screens using PANAC with improved activity for 
the formation of penicillin G [5] were verified using PACoA [30].  PANAC [37] is also 
more hydrophobic than PACoA [30] so 5% THF was required to dissolve it.  However, 
the presence of organic solvent was found not to be detrimental to AT activity (Cheung 
2006). 
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Scheme 2.2 To compare Coenzyme A with N-acetylcysteamine  
2.3.4 Medium Throughput Amylose Affinity Membrane Screen 
Another screening method was then developed by previous group members (Cheung 
2006; Khara 2007) which avoided the use of robotic equipment that was not available to 
the group in Manchester.  This time, a medium throughput method, which utilised an 
amylose affinity membrane (Cattoli and Sarti 2002) that AT-MBP fusion proteins could 
bind to was employed.  The screening procedure was also used by the author and is 
detailed below and shown in Figure 2.1.  (For more experimental detail see § 6.5.1). 
E. coli colonies containing the AT clones are grown on agar plates supplemented with 
chloramphenicol (30 µg mL -1) and IPTG (0.3 mM).  The colonies are then ‘lifted’ using 
an amylose affinity membrane.  Whilst on the membrane the cells are lysed to release 
the AT-MBP fusion protein, which binds to the membrane via MBP-amylose affinity, 
exposing AT on the surface of the membrane.  In the meantime, the original agar 
‘master’ plate is incubated further to regenerate the colonies then stored until required at 
4 ˚C. 
Substrates, i.e. penicillin or cephalosporin nucleus plus acyl donor, can be sprayed onto 
the membrane at this point and allowed to react, catalysed by the AT present on the 
membrane.  The membrane is then placed face down onto an agar plate containing the 
super sensitive E. coli strain, E. coli ESS, and the whole assembly incubated.  
Alternatively, substrates can be added directly to the E. coli ESS-agar plate.  Kill zones 
 54 
in the E. coli ESS-agar plate, observed as clear halos, correspond to the formation of 
antibiotic, with larger kill zones indicating greater AT acylation activity.  The colony 
responsible can then be selected from the ‘master’ plate for further investigation. 
For screen development and initial screening the natural AT conversion of 6-APA [1] to 
penicillin G [5] formation was used.  As already hinted, the method of substrate 
application in the screen depended on the solubility of the acyl donor; less soluble 
substrates were sprayed as aqueous solutions containing 5% THF onto the membrane, 
more soluble substrates were added to the agar during E. coli ESS-agar plate 
preparation. 
 
Figure 2.1 A diagram to show the amylose affinity membrane screen 
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This screening procedure was used to screen the library with great success and a 
number of useful AT acylation mutants were identified.  In total, approximately 50,000 
clones were rapidly screened, which led to the identification of 7 new residues of 
interest that could not have been predicted from crystal structure data due to their 
distant locations from the active site of AT (Khara 2007). 
These residues were recombined in various permutations and the resulting 
recombinants’ activity determined for the acylation of 6-APA with AdiNAC [33], 
PANAC [37] and PACoA [30] (Khara 2007).  In the case of the adipoyl side chain, only 
mutants with good activity with AdiNAC [33] were investigated with AdiCoA [32] due 
to the expense of the substrate. Recombination of the mutations generally had a 
cumulative effect on activity.  Particularly noteworthy was the recombinant Asp34Asn 
Ala106Val His182Asn His219Tyr.  This was found to have a 30 fold improvement on 
wild type activity for the formation of AdiPen [26] from 6-APA [1] and AdiCoA [32] 
(18 fold improvement when AdiNAC [33] was used). 
A summary of the recombinants and their activities is shown in Table 2.1.  Four crosses 
represents wild type activity, minus represents a dramatic loss in the substrate activity.  
Comparisons can only be made within, but not between columns as PACoA [30] is a 
much better co-substrate than PANAC [37] or AdiNAC [33], and AdiCoA [32] is a 
better co-substrate than AdiNAC [33]. 
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Table 2.1 AT Recombinants with improved acylation activity (Khara 2007) 
Amino Acid Change PACoA PANAC AdiNAC AdiCoA 
wt + + + +  + + + + + + + + + + + + 
Single Mutations 
D34N + + + + + + + (+) + + + (+) ND 
K64E + + + + 
(+) 
+ + + + 
(+) 
+ + + +  ND 
K97R* + + + + 
(+) 
+ + + + 
(+) 
+ + + + 
(+) 
+ + + + + 
A106V + + + + + 
(+) 
+ + + + 
(+) 
+ + + + + + + + + + 
+ + + 
H182N + (+) + + (+) + + + + + 
+ 
+ + + + + 
+ + + (+) 
H219Y + + + + +  + + + + 
(+) 
+ + + + 
(+) 
+ + + + 
(+)  
N239K + + + + +  + + + + 
(+) 
+ + ND 
G278R + + + + + + + + + 
(+) 
+ + + + 
(+) 
ND 
Double Recombinants 
K97R H219Y + + + + + 
+ 
+ + + + + 
+ 
+ + + + + ND 
K97R N239K + + + + + 
(+) 
+ + + + 
(+) 
+ + + + ND 
H219 N239K + + + + + 
+ 
+ + + + 
(+) 
+ + + + + + + + 
(+) 
D34N A106V + + + + + 
+ 
+ + + + 
(+) 
+ + + + 
(+) 
+ + + + + 
+ + + + + 
K39E K64E + + + + + + + + + + 
(+) 
ND 
A106V H182N + + + + + + (+) + + + + + 
(+) 
+ + + + + 
+ (+) 
K39E H182N (+) + + + + + + 
(+) 
ND 
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H182N H219Y + (+) + + + + + 
+ 
ND 
K39E A106V + (+) + + + + + 
+ 
+ + + + + ND 
A106V H219Y + + + + + 
+ 
+ + + + 
(+) 
+ + + + 
(+) 
+ + + + + 
+ + (+) 
K39E H219Y + + + + + + + + + + 
(+) 
ND 
Triple Recombinants 
K97R H219Y N239K + + + + + 
+ +  
+ + + + + 
+ (+) 
+ + + + 
(+) 
+ + + + 
(+) 
K39E A106V H182N (+) + + + + + + + 
+ + 
ND 
K39E H182N H219Y (+) + (+) + + + + + 
+ + 
ND 
K39E A106V H219Y + (+) + + + + + 
(+) 
+ + + + + 
+ (+) 
ND 
A106V H182N H219Y + + + (+) + + + (+) + + + + + 
+ + (+) 
+ + + + + 
+ + + + + 
(+) 
A106V H219Y N239K + + + + + 
(+) 
+ + + + + 
(+) 
+ + + + + 
(+) 
+ + + + + 
+ + + + + 
(+) 
Quadruple Recombinants 
D34N A106V H182N H219Y + + + + + + + + + 
(+) 
+ + + + + 
+ + + + + 
+ + + + + 
+ + + + + 
+ + + + + 
(+) 
K97R A106V H219Y N239K + + + + + 
+ +  
+ + + + + 
+ (+) 
+ + + + + 
(+) 
+ + + + + 
+ + +  
Quintuple Recombinant 
D34N K97R A106V H219Y N239K + + + + + 
+ + (+) 
+ + + + + + + + + + + + + + + 
+ + + + + 
ND = not determined.  
*Rational mutant 
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 2.4 Further Library Screening 
The author continued screening the high mutation library using the amylose affinity 
membrane screen, for mutants with improved activity, with respect to wild type AT, for 
the formation of AdiPen [26] from 6-APA [1] and AdiNAC [33]. 
In total approximately 10,000 clones were screened.  This led to the initial identification 
of 60 colonies that had increased activity with respect to wild type AT.  In order to 
verify this result and narrow down these possibilities further, the colonies were tooth 
picked onto an agar plate in a grid to give a new master plate and re-assayed using the 
amylose affinity screen.  This resulted in a final six candidates that showed the most 
improvement in activity when compared to wild type AT. 
DNA sequencing revealed three of these to be wild type, two contained the single 
mutation, Gly278Arg, which had been found previously by former group member, 
Khara (Khara 2007).  The final variant was the double mutant, Arg70Leu Asn267Ser, 
not found in previous screens. 
Obtaining wild type AT from the screen can be explained when colony size is 
considered.  In the initial screen the colonies would not have all been the same size due 
to various growth factors.  It was also impossible during the tooth picking process to 
ensure a uniform colony size.  Larger colonies will give larger kill zones due to the 
increased amount of AT present and not necessarily because the AT present is any more 
active than wild type.  It was quite difficult in practice to take into account the relative 
size of the colony, compared to the size of kill zone it subsequently produced.  This 
perhaps goes towards explaining why of the clones selected from the screen, 50% were 
wild type. 
The reoccurrence between screens of the single mutant Gly278Arg implies that the 
method used to sample the library is sufficient.  It is likely that the library had been 
thoroughly screened at this point and most of the mutants contained in the library with 
improved activity for the acylation of 6-APA [1] with various side chains identified. 
This leaves the double mutant Arg70Leu Asn267Ser, which was investigated further as 
follows.  As well as comparing with wild type AT, it was decided to compare the 
mutants obtained from the screen with Asp34Asn Ala106Val.  This double mutant had 
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been obtained from a screen by previous group member Khara (Khara 2007) and was 
found to have a considerably greater activity than wild type AT for the acylation of 6-
APA [1] with both the phenyl acyl (PANAC [37] and PACoA [30]) and adipoyl side 
chains (ADiNAC [33] and AdiCoA [32]) (§ Table 2.1). 
The proteins were expressed and purified then characterised by SDS-PAGE to ensure 
post-translational cleavage had occured.  Initial kinetic studies (§ 6.6) were carried out 
for the conversion of AdiPen [26] from 6-APA [1] and AdiNAC [33].  The data 
obtained showed that Arg70Leu Asn267Ser did have improved activity when compared 
with wild type AT although it was not quite as improved as that of Asp34Asn 
Ala106Val (Figure 2.2).  However, at this stage it was not known whether both the 
mutations, Arg70Leu and Asn267Ser, contributed equally to the observed activity of 
Arg70Leu Asn267Ser.  It was possible that either was much superior to the other or that 
one had no contribution towards the observed activity or indeed, had a deleterious effect 
on the overall activity.  It was therefore desirable to separate the double mutant into its 
constituent single mutants to determine their individual effect on activity. 
 
Figure 2.2 A graph to show the rate of formation of AdiPen [26] for various AT 
  mutants 
Site directed mutagenesis was used to obtain the Arg70Leu and Asn267Ser as single 
mutations for further kinetic studies. The proteins were expressed, purified then 
characterised by SDS-PAGE as before.  Kinetic studies were carried out as before for 
the conversion of AdiPen [26] from 6-APA [1] and AdiNAC [33].  It was found that the 
 60 
mutations individually did not contribute equally to the activity that had been observed 
for the double mutant.  In fact, Arg70Leu had a decrease in activity when compared to 
wild type AT.  However, Asn267Ser was found to have a much improved activity when 
compared with both the double mutant Arg70Leu Asn267Ser, and wild type AT and its 
activity was comparable to that of Asp34Asn Ala106Val (data not shown).  To 
summarise, the activity of the various mutants went in the order: 
Arg70Leu < wild type < Arg70Leu Asn267Ser < Asn267Ser = Asp34Asn Ala106Val 
The fact that the activity of Arg70Leu had a lower activity than wild type and 
Asn267Ser was much higher was interesting but perhaps not so surprising.  It was 
speculated that as AT uses coenzyme A derivatives as substrates, the presence of an AT 
variant with improved activity in E. coli could have a detrimental effect on cell growth, 
perhaps by hydrolysing any coenzyme A derivatives required by E. coli for growth.  If 
this were the case it would have implications for the screening process. 
Colonies containing AT mutants with increased activity would display less growth, 
therefore less AT would be present, resulting in a smaller kill zone, which would not 
lead to selection of the mutant from the screen.  However, the presence of a weaker 
mutation allows stronger mutants to be found as the weaker mutant enables the colony 
to grow as normal, therefore compensating for the stronger mutants lack of growth thus 
leading to selection of the desired stronger mutant from the screen.  In this case, 
Arg70Leu as the weaker mutant allowed colony growth ensuring the selection of the 
stronger Asn267Ser mutant from the screen. 
Potentially, this means that mutants with increased activity would not be selected from 
the screen unless they are coupled with a less active mutant.  A possible solution to this 
problem would be to add IPTG after a period of colony growth before cell lysis thus 
ensuring uniform colony growth and a fairer comparison of the resultant kill zones.  
During the employed screening process, the inducer, IPTG, was present in the agar 
plates from the beginning of colony growth. 
It was also observed that protein expression levels for variants were generally lower 
than those of wild type.  When expressing AT, the E. coli cell cultures undergo a growth 
period before expression is induced with the addition of IPTG.  In principle, no AT 
should be present during this growth period.  However, AT expression is under the 
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control of the lac operon which is known to be ‘leaky’, that is to say some protein is 
expressed before induction.  Protein expression can be more tightly regulated with the 
use of the lacIq gene, a mutated version of the lacI gene that leads to increased levels of 
the lac repressor.  Although pHAR10a does have the lacIq gene, there were doubts as to 
its integrity; it was believed there was a deletion in the gene (Shorrock 1998) and some 
even doubted its presence at all due to the derivation of the pHAR10a plasmid from the 
pUC series which contain truncated versions of the lacIq gene (Derome 2003).  
However, this can be compensated for by using a host strain that does contain the lacIq 
gene, like XL1-Blue.  However, even with the use of the lacIq gene, protein expression 
is not completely repressed; there is at least 30% AT expression without IPTG (Hart 
1996; Shorrock 1998). 
As the results of the kinetic studies showed an improvement in acylation with 
Asn267Ser it was decided to investigate the effect of the mutation further by combining 
with the individual mutations, Asp34Asn and Ala106Val, in various permutations in 
order to determine whether the improvement in activity observed for Asn267Ser would 
be additive as had been previously found for other mutations (Khara 2007). 
The following mutants were made accordingly by site directed mutagenesis: the double 
mutants, Asp34Asn Asn267Ser and Ala106Val Asn267Ser and the triple mutant 
Asp34Asn Ala106Val Asn267Ser.  The proteins were expressed and purified then 
characterised by SDS-PAGE as before. 
Kinetic studies were again carried out as before for the conversion of AdiPen [26] from 
6-APA [1] and AdiNAC [33] to determine the effect of the Asn267Ser mutation.  When 
combined with Asp34Asn there was no improvement in activity on Asp34Asn alone 
and the double mutant Asp34Asn Asn267Ser was only comparable to wild type activity.  
When combined with Ala106Val there was a big improvement, the activity was greater 
than that observed for Asn267Ser alone and the double Asp34Asn Ala106Val.  In the 
case of the triple mutant, Asp34Asn Ala106Val Asn267Ser, there was the greatest 
improvement in activity (§ Figure 2.3). 
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Figure 2.3 A graph to show the rate of formation of AdiPen [26] for various AT 
  mutants 
Overall the results showed that the inclusion of Asn267Ser did indeed have an additive 
effect on activity when combined with other mutations, except when combined with 
Asp34Asn.  However, there was no detrimental effect on activity when Asn267Ser was 
combined with Asp34Asn.  These results were reproduced when AdiCoA [32] was used 
as the acyl donor (data not shown).  To summarise, the activity of the various mutants 
was of the following order: 
wild type = Asp34Asn = Asp34Asn Asn267Ser < Asn267Ser = Asp34Asn Ala106Val < 
Ala106Val Asn267Ser < Asp34Asn Ala106Val Asn267Ser 
When the amino acid sequences for the penDE gene from P. chrysogenum and 
A. nidulans were compared it was found that the sequences differed in the same way at 
this point with asparagine at position 267 in P. chrysogenum and serine in A. nidulans 
which further corroborates the suggestion that the substrate specificities for AT from 
each organism may differ (§ 2.2.2). 
2.5 Chapter 2 Summary 
Screening of the high mutation library using the amylose affinity membrane procedure 
led to the selection of the double mutant Arg70Leu Asn267Ser.  Upon further 
investigation although the individual mutation Arg70Leu had decreased activity for the 
formation of AdiPen [26] from 6-APA [1] and AdiNAC [33], the Asn267Ser single 
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showed a large improvement on wild type activity.  Recombination led to the formation 
of the triple mutant Asp34Asn Ala106Val Asn267Ser, which showed an even greater 
improvement for the acylation of 6-APA [1]. 
Selection of the previously identified Gly278Arg mutant suggested the library had been 
sufficiently screened for acylation of 6-APA [1].  Attention is now turned to using the 
amylose affinity membrane screen in order to identify beneficial mutants for the 
acylation of cephalosporin substrates. 
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3.1 Introduction 
Since a number of AT mutants with improved acylation activity had been identified, 
attention was turned to identifying AT mutants with improved hydrolysis activity.  In 
order to do this a selection or screening method was needed.  Unfortunately, the 
amylose affinity screening method was not suitable for this purpose. 
The amylose affinity screening method takes advantage of the fact that during the 
course of the acylation reaction, 6-APA [1] is converted into its antibiotic, acylated 
form.  However, during the course of hydrolysis the opposite occurs: the bioactive IPN 
[18] is converted into the less bioactive substrate, 6-APA [1].  If the amylose affinity 
screening method were used to find mutants with improved hydroysis activity, the E. 
coli ESS would be killed at the beginning of the screen and therefore would not indicate 
hydrolysis.  Retrospective application of E. coli ESS during the screening process once 
the hydrolysis had been allowed to take place was considered.  However, in practice this 
was not feasible therefore another approach was needed. 
When considering the hydrolysis step independently from the acylation step there is one 
major issue that needs to be addressed by any screening or selection method.  When 
IPN [18] is hydrolysed, 6-APA [1] is formed which remains in the active site of AT.  In 
normal circumstances 6-APA [1] is re-acylated by AT.  However, if no acylation takes 
place, as would be the case for any hydrolysis screening or selection method, 6-APA [1] 
will remain in the active site of AT as 6-APA [1] has a high affinity for AT.  6-APA [1] 
blocks the active site of AT to further molecules of IPN [18] therefore effectively acting 
as an inhibitor of AT hydrolysis.  A screening or selection method for the identification 
of hydrolysis mutants needs to overcome this problem.  In principle there are two mains 
ways this problem could be addressed.  One approach would be to have a highly 
sensitive screening or selection method, which would be able to detect the small 
concentrations of IPN [18] and 6-APA [1] involved.  Another approach would be to 
somehow remove 6-APA [1] from the active site. 
3.1.1 The Periplasmic Expression of AT 
One way to perhaps increase the sensitivity of any assay would be to increase the 
amount of AT present.  Although each molecule of AT would perhaps only hydrolyse 
one molecule of IPN [18] if there was lots of AT present the overall amount of IPN [18] 
 66 
hydrolysed to 6-APA [1] would be greater which would be easier to detect.  In order to 
increase the amount of AT available the expression of AT in the periplasm of E. coli 
was considered. 
The periplasm is the region of space between the inner and outer membranes of gram-
negative bacteria such as E. coli and could be considered as the first line of defence of 
bacteria towards antibiotics.  While AT is located in the cytoplasm of E. coli, IPN [18] 
can cross the outer membrane into the periplasmic space where it can inhibit cell wall 
formation thus killing the cell.  However, if AT was also present in the periplasm it 
could hydrolyse and therefore inactivate the IPN [18] present allowing survival of the 
cell.  This situation would be comparable to the presence of β-lactamases in bacteria, 
which also operate in the periplasm and protect the organism by hydrolysing the β-
lactam ring of β-lactam antibiotics (§ 1.4.1).  Plating the library on IPN [18] 
concentrations at MIC or higher would enable life/death selection; mutants capable of 
destroying IPN [18] due to their increased hydrolytic capability would result in the 
survival of the corresponding colony.  Selection of the colony would lead to 
identification of the responsible mutant from the library.  Wild type AT or mutants with 
wild type activity or lower would not be able to inactivate IPN [18] by hydrolysis and 
therefore would not survive. 
3.1.2 Targeting Proteins to the Periplasm 
In 1999, Günter Blobel was awarded a Nobel Prize for recognising that “proteins have 
intrinsic signals that govern their transport and localisation in the cell.”  In bacteria there 
are many proteins that are secreted into the periplasm (e.g. OmpA, OmpT, PelB, β-
lactamase, alkaline phosphatase) and a key feature of these proteins that determines 
their fate is that they have a leader or signal peptide sequence.  These signal sequences 
are usually between 15-30 amino acids long and consist of a hydrophobic core with 
positive residues at the N-terminus and polar uncharged residues at the C-terminus (von 
Heijne 1983; von Heijne 1986).  The mechanisms by which these signal peptides direct 
proteins across the bacterial plasma membrane have been extensively studied and 
reviewed (Baneyx 1999; Driessen, Manting et al. 2001; Rapoport 2007) and can be 
briefly summarised as follows. 
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Pre-proteins are synthesised in the cytosol with the signal peptide at the N-terminus and 
are then guided to the translocation machinery at the cytoplasmic membrane by 
chaperone molecules, either the signal recognition peptide (SRP) or the protein SecB.  
SRP recognises hydrophobic signal sequences or segments and targets the emerging 
nascent protein co-translationally.  However, most pre-proteins are targeted post-
translationally by SecB (§ Figure 3.1). 
SecB does not interact with the signal peptide itself but binds to the mature domain of 
nascent proteins.  SecB stabilises the nascent protein in a denatured conformation 
presumably by allowing the protein to wrap around it.  The signal peptide is believed to 
both prevent folding of the protein, as folded proteins are not translocated, and also play 
a role in binding the resulting SecB-protein complex to the translocase machinery. 
SecB then delivers the protein to the translocase machinery at the membrane of the cell.  
This consists of a protein pore, SecYEG, and the ATP driven, molecular motor protein, 
SecA.  The SecB-protein complex binds to SecA and repeated cycles of ATP binding 
and hydrolysis, and protein binding and release, lead to a stepwise translocation of the 
protein across the membrane.  Once the protein has been exported into the periplasm, 
the signal peptide is then cleaved by a peptidase. 
The use of signal peptides has been exploited in recombinant technology in order to 
direct proteins of interest to the periplasm for various purposes (Baneyx 1999; Sorensen 
and Mortensen 2005).  The use of signal peptide-AT fusions in order to allow secretion 
of AT in the periplasm of E. coli, would potentially enable the development of a 
life/death selection method for the identification of improved hydrolysis activity AT 
mutants. 
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Figure 3.1 Model for Sec-B mediated protein targeting 1.) SecB binds to the mature 
  domain of a nascent protein.  2.) SecB stabilises the protein in denatured 
  conformations.  3.) The SecB-protein complex is targeted to the SecYEG 
  bound SecA.  4.) The signal peptide binds to SecA inducing release of 
  the protein from SecB to SecA.  This release is coupled with ATP  
  binding (Driessen, Manting et al. 2001). 
3.1.3 Previous Work 
Targeting AT to the periplasm using signal peptides had been considered previously in 
the group (Hart 1996).  Firstly, the use of the β-lactamase signal peptide was 
investigated.  The success of this approach had already been demonstrated in the case of 
chicken muscle triosephosphate isomerase, a cytoplasmic protein.  By fusing with the 
signal peptide of β-lactamase plus the first 12 residues of the mature β-lactamase, 
chicken muscle triosephosphate isomerase was successfully secreted into the periplasm 
of E. coli (Summers and Knowles 1989).  However, when the same approach was taken 
with AT, only unprocessed, aggregated protein was obtained which did not show any 
AAT activity (Hart 1996). 
The use of maltose binding protein (MBP) was also explored.  Like β-lactamase, MBP 
is a periplasmic protein.  Various studies had shown that fusion of various proteins with 
MBP resulted in the secretion of the protein of interest in the periplasm (Bedouelle and 
Duplay 1988; Di Guan, Li et al. 1988; Blondel and Bedouelle 1990; Blondel and 
Bedouelle 1991).  The resulting MBP-protein fusions could also be purified using 
amylose affinity chromatography.  MBP-AT fusions were constructed unfortunately, 
only unprocessed protein which did not show any AAT activity was produced (Hart 
1996). 
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Fortunately, for the author, new crystallographic information became available which 
allowed us to reconsider the secretion of AT into the periplasm using signal peptides.  A 
salt bridge between the N-terminus of AT and the side chain carboxylate of Glu338 was 
believed to be present, in which case fusion of signal peptides to the N-terminus would 
have implications for the processing and activity of AT (§ Figure 3.2) (Dijkstra 2007). 
 
Figure 3.2  To show the location of the salt bridge in AT 
3.1.4 The Role of Salt Bridges in Proteins 
Salt bridges play an important role in the structure and function of proteins.  Surface salt 
bridges help aid solubility.  It has also been implied that salt bridges increase the 
specificity of folding because there are only a few ways of packing charged groups in a 
protein while there are many ways of energetically equivalent packing of hydrophobic 
groups.  The presence of charged groups in a protein are also believed to provide 
suitable environments for catalysis and protein-ligand binding (Bosshard, Marti et al. 
2004). 
Whether the formation of a salt bridge in a protein is stabilizing or destabilizing is 
subject to much experimental and theoretical investigation.  The observation that 
thermophilic proteins contain more salt bridges than their mesophilic counterparts 
would suggest they play a stabilising role, however, there is evidence in favour of both 
(Waldburger, Schildbach et al. 1995; Kumar and Nussinov 2002).  
A salt bridge can be defined as a pH-dependent non-covalent bond between oppositely 
charged residues that are sufficiently close to each other to experience electrostatic 
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attraction (Bosshard, Marti et al. 2004).  At physiological pH, electrostatic interactions 
can arise between a pair of ionisable side chains or between ionisable side chains and 
the termini of the backbone (negative charges from aspartate, glutamate, tyrosine, 
cysteine or the C-terminal carboxylate group, and positive charges from histidine, 
lysine, arginine or the N-terminal amino group). 
There are a number of factors that contribute to the strength and stability of a salt bridge 
in a protein (Pace, Grimsley et al. 2009).  The strength of the Coulombic force between 
the charges depends on pH, the distance between the charges and their geometry.  
Interactions (i.e. van der Waals forces, hydrogen bonds) are also then possible with 
other ionizable side chains and the dipoles in the peptide bonds of the backbone of the 
protein and other polar non-ionizable side chains in the vicinity.  The stability of a salt 
bridge is a balance between these interactions and enthalpy effects due to desolvation 
(the ions must be desolvated before they can interact) and backbone entropy.  The 
location of the salt bridge is also important.  Salt bridges on the surface of a protein are 
subject to an aqueous environment where interaction with and solvation by water are 
factors, whereas salt bridges buried in the interior of the protein are in a low dielectric, 
hydrophobic environment (Tanford 1978). 
In order to determine the effect of a salt bridge on protein stability, two experimental 
approaches are used which allow the stability of a protein to be determined by 
comparing the difference between the free energy of its folded and unfolded state. 
The salt bridge can be broken by altering the pH in such a way that the acidic group is 
protonated or the basic group is deprotonated.  This is a non-invasive technique, which 
gives a relative value.  pKa’s can then be measured using NMR.  In one study using this 
technique, the presence of a salt bridge in T4 lysozyme was found to stabilize the native 
state by 3-5 kcal mol-1 (Anderson, Becktel et al. 1990). 
Site directed mutagenesis can also be used to investigate the effect of salt bridges.  
Charged residues are mutated to non-ionizable groups and their effect on protein 
stability determined.  However, this technique is not ideal as although the charges are 
removed the structure of the residue is also altered which can lead to the disruption of 
other interactions that the side chain played a role in thus altering the protein 
conformation.  This problem can be partially addressed using double mutant cycles 
(Horovitz and Fersht 1990) where each residue of the pair is mutated individually then 
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together.  This approach is sensitive to the fact that proteins are highly co-operative 
structures and the interaction between the residues may not be direct but propagated 
through the molecule; the residues are considered to be coupled to one another.  There 
are number of examples where this approach has been employed to investigate surface 
salt bridges (Serrano, Horovitz et al. 1990; Strop and Mayo 2000; Marti and Bosshard 
2003). 
Computational methods have also been successfully employed in analyzing the 
stabilizing effects of salt bridges.  In one example, where the energetics of solvent-
exposed ion pairs were analysed, the method employed was found to be accurate to 
within a few kJ mol-1 (Luo, David et al. 1999). 
A greater understanding of how salt bridges affect proteins would allow the design of 
more stable proteins and the subject has been extensively reviewed (Kumar and 
Nussinov 2002; Bosshard, Marti et al. 2004; Baldwin 2007). 
3.1.5 The Salt Bridge in AT and its Implications for MBP-AT Fusions 
It is generally accepted that the removal of one of the charges from the ion pair that 
make up a salt bridge decreases the stability of the protein, especially in the case of 
buried salt bridges as the remaining charge cannot be stabilised due to the hydrophobic 
environment of the protein core.  However, in the case of AT, the salt bridge was 
observed on the surface of the protein.  The removal of a charge from a surface salt 
bridge is also believed to be destabilising.  In one study investigating the electrostatic 
interactions between the proteins in leucine zippers, it was found that the replacement of 
a single ion pair partner by an uncharged residue resulted in a less stable dimer (Marti 
and Bosshard 2003). 
The salt bridge in AT is between the main chain nitrogen of Met1 and the side chain 
carboxylate of Glu338.  In a study investigating surface salt bridges in a 
hyperthermophilic rubredoxin variant, it was found that a main chain to side chain salt 
bridge was more stabilising than a side chain to side chain salt bridge.  It was 
rationalised that the entropy cost of making a salt bridge with the backbone is less, due 
to the backbone having been immobilised upon protein folding (Strop and Mayo 2000). 
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By fusing signal peptides onto the N-terminus of AT it is apparent that the salt bridge 
had been disrupted, hence affecting the stability of the resulting signal peptide-AT 
fusion.  This would explain the previous observations of unprocessed, inactive AT for 
both the β-lactamase and MBP protein fusions (Hart 1996). 
The presence of the signal peptide on the N-terminus would remove the positive charge 
of the ion-pair making up the salt bridge, leaving the negative charge exposed.  One 
way to remove this negative charge would be to replace the Glu338 residue for a neutral 
residue using site directed mutagenesis in order to hopefully restore the stability to AT. 
As has already been discussed, when removing a charge by substitution with another 
residue there are other subtleties to be aware of, interactions the side chain was involved 
with and the effect on the overall conformation of the protein.  To replace Glu338, a 
non-ionisable, neutral residue was required with some consideration to sterics.  A range 
of substitutions could have been made and their effect studied in order to find the ideal 
candidate.  However, when discussing the problem, the crystallographer was confident 
that substituting glutamate for serine was the obvious choice (Dijkstra 2007).  The salt 
bridge between the N-terminus (Met1) and Glu338 and the effects of MBP fusion and 
Glu338Ser mutation are depicted below in Scheme 3.1. 
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Scheme 3.1 To show the effect of MBP and Glu338Ser on the salt bridge of AT 
Either of the previous signal peptide-AT fusion strategies for secreting AT into the 
periplasm of E. coli could have been revisited.  However, it was decided to reinvestigate 
the MBP-AT fusions and not the β-lactamase-AT fusions.   
 73 
There are advantages to using MBP over β-lactamase.  Firstly, the resulting MBP-AT 
fusion can be purified using amylose affinity chromatography.  Also, it has been shown 
that the presence of MBP enhances the solubility of proteins minimising inclusion body 
formation (Kapust and Waugh 1999).  Another advantage is that MBP does not contain 
any cysteine residues that could interfere with disulfide bond formation within the target 
peptide (Di Guan, Li et al. 1988). 
3.1.6 Construction of malE-penDE fusion plasmid pHAR-4p 
The plasmid (pHAR4-p) used in this work was constructed by previous group member 
Darren Hart (Hart 1996) as follows.  The commercially available pMAL-p2 vector from 
New England Biolabs® Inc was used.  This contains the malE gene, which encodes 
MBP and is under the control of a strong tac promoter.  A multiple cloning site (MCS) 
and polyasparagine linker are also present, fused onto the 3´ end of the malE gene 
allowing the gene of interest to be fused directly.  There is also a recognition site for the 
protease Factor Xa, which allows the protein of interest to be cleaved from the MBP 
after purification if required. 
The penDE gene was excised from another plasmid by first of all changing the Nde I 
restriction site at the beginning of the gene to an Sph I site using site directed 
mutagenesis, then digesting with Sph I.  The resultant overhangs were blunt ended with 
T4 DNA polymerase.  Unfortunately, this led to the removal of Met1 from AT.  The 
penDE blunt end/Hind III fragment was then ligated into the pMAL-p2 backbone, 
which had been digested using Xmn I (blunt ends) and Hind III. 
The pMAL-p2 vector also contains a gene (bla) encoding for ampicillin resistance.  The 
presence of β-lactamase was undesirable as it can also hydrolyse β-lactam antibiotics, 
therefore the gene was inactivated by inserting a commercially available 
chloramphenicol resistance cassette.  E. coli contains chromosomally encoded β-
lactamase which one had to be aware of when using crude protein extracts.  However, 
when purified using amylose affinity chromatography this would not be a problem, as 
the β-lactamase would not be retained by the amylose resin. 
There were implications to the inadvertent removal of Met1.  By placing the MBP onto 
the N-terminus of AT it was believed that the salt bridge in which it had participated 
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was a combination of both the MBP fusion and the removal of Met1 that was so 
detrimental to the processing and activity of AT and maybe if the MBP had been fused 
directly onto a methionine at position 1, as had been supposed, the effect would not 
have been so catastrophic.  Therefore it was decided that as well as mutating Glu338 to 
serine, Met1 would also be restored using site directed mutagenesis. 
As a result of the cloning process, position 1 in AT was now effectively the final amino 
acid in the polylinker, an arginine residue.  This was also part of the Factor Xa 
recognition site.  Factor Xa cleaves the amino acid sequence Ile-Glu/Asp-Gly-Arg 
directly after the arginine residue, so making this mutation would forego the possibility 
of cleaving the MBP from AT if required.  However, it had been found previously that 
the presence of MBP on the C-terminus of AT (plasmid pHAR10a) did not hinder 
activity so cleavage was not necessary (Hart 1996).  It was anticipated that this would 
also be the case when MBP was fused onto the N-terminus of AT. 
Coincidentally, it should be noted that as an ionisable side chain, arginine exists as a 
positive ion at physiological pH.  Arginine is the most basic amino acid.  This basicity 
is due to the presence of the guanidinium group at the terminus of arginine’s side chain.  
It has been found that the stability of salt bridges increase as the basicity of the amino 
acid also increases (Prell, O'Brien et al. 2009).  However, in the case of AT the positive 
ion required for the salt bridge formation comes from the backbone nitrogen of the 
amino acid at position 1 and not the side chain.  The possibility of the positive charge of 
the Arg1 side chain restoring the positive ion pairing of the salt bridge is remote due to 
the rearrangement in the conformation of the amino acid that would be required in order 
for it to act as a counter ion to the negative charge of Glu338.  One assumes that as 
unprocessed, inactive AT was obtained that this indeed did not occur. 
3.2.1 Verification of plasmid pHAR4-p 
As the plasmid pHAR4-p had been in storage for a number of years, preliminary 
experiments sought to verify its integrity.  The plasmid had been stored as a precipitate 
and was therefore re-suspended in sterile Milli-Q H2O and the concentration of the 
resulting solution determined by agarose gel electrophoresis (§ 6.2.3).  The plasmid was 
then transformed into XL1-Blue supercompetent cells using the heat shock method (§ 
6.3.4) and glycerol stocks prepared. 
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Growth and harvestation of the cells (§ 6.4.1) enabled DNA to be isolated which was 
then analysed by restriction digest.  The plasmid cut as expected and the results were 
also compared with the previous work, which was reproduced. 
3.2.2 Site Directed Mutagenesis of pHAR4-p 
Site directed mutagenesis (§ 6.3.1) was performed on pHAR4-p to obtain Arg1Met and 
Glu338Ser.  The mutations were verified by restriction digest vide supra and DNA 
sequencing (§ 6.2.5.  For primers see Appendix D). 
3.2.3 MBP-AT Fusion Protein Expression and Analysis 
Proteins were expressed from pHAR4-p (wild type), Arg1Met and Glu338Ser.  Due to 
the smaller volume of the periplasm compared to the cytoplasm, protein expression was 
carried out on a larger scale, 5× 100 mL as opposed to the 1× 100 mL scale carried out 
for cytoplasmic expression of AT (§ Chapter 2).  The resulting cell pellets from 
subsequent growth and harvestation were fractionated in order to obtain the cytoplasmic 
and periplasmic fractions separately (§ 6.4.5). 
SDS-PAGE (§ 6.4.8) analysis of the crude single mutants Arg1Met and Glu338Ser 
cytoplasmic and periplasmic proteins showed lots of protein bands making it difficult to 
identify the bands corresponding to the MBP-AT fusion protein i.e. 51 kDa for the 
MBP-α subunit (40 + 11 kDa) and 29 kDa for the β-subunit. 
The activity of the crude AT mutant proteins with respect to the formation of Pen G [5] 
from 6-APA [1] and PANAC [37] was determined (§ 6.6.3).  The formation of Pen G 
[5] from 6-APA [1] was selected for this purpose as it is the natural reaction of wild 
type AT.  Both single mutants, Arg1Met and Glu338Ser, showed activity.  It was found 
for both Arg1Met and Glu338Ser that the crude cytoplasmic protein gave greater kill 
zones than the crude periplasmic protein.  The mutant Glu338Ser also gave slightly 
larger kill zones than the Arg1Met mutant for both the cytoplasmic and periplasmic 
fractions.  However, as crude protein preparations were used, these differences in 
activity may have been due to differences in the actual amount of AT present, which 
had not been quantified.   
These initial results were very encouraging.  Although activity was observed for both 
the cytoplasmic and periplasmic fractions of the single mutants, it was not observed for 
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either of the protein fractions obtained from pHAR4-p (wild type).  This suggested that 
activity had been restored to AT by the mutations made.  However, it was not clear at 
this stage whether AT had been successfully targeted to the periplasm although previous 
work would suggest it had (Hart 1996).  The results also show that the presence of MBP 
at the N-terminus of AT has no effect on its activity as had been anticipated due to the 
observation that when MBP was present at the C-terminus of AT it was still active (§ 
Chapter 2). 
As active AT was formed it would also suggest that the salt bridge was not essential for 
correct folding of AT.  It is also speculated that any solubility properties that the surface 
salt bridge may have imparted to AT were perhaps compensated for by the presence of 
MBP, which is known to enhance the solubility of proteins vide supra. 
The observed activity for the Arg1Met mutant was quite surprising.  The side chain of 
any residue at position 1 was not deemed to have any role in the salt bridge; it was the 
backbone of the amino acid at this position that played a role in the salt bridge. By 
placing the MBP here it had prevented it from carrying out its role, leaving a 
destabilising lone negative charge at Glu338.  However, arginine is also charged and 
perhaps the positive charge of the arginine side chain also had a destabilising effect on 
AT the effect of which was neutralised by this mutation. 
In the case of the Glu338Ser mutant, replacing the negative glutamate residue with the 
neutral serine residue had the desired effect; the instability due to the presence of the 
lone negative charge at this position had indeed been mitigated. 
The crude protein preparations were also purified using affinity chromatography (§ 
6.4.6).  However, presumably due to the scale of protein employed, loading and elution 
of protein to and from the column was difficult.  Initial SDS-PAGE analysis showed 
very faint protein bands, which were difficult to assign with certainty.  The extended 
length of the protein purification procedure due to handling issues also lead to doubts to 
the integrity and stability of any resulting protein. 
As the removal of one destabilising charge, either positive as in the case of Arg1Met or 
negative as for Glu338Ser, restored activity to AT, it was anticipated that the removal of 
both the charges via the double mutant Arg1Met Glu338Ser, would lead to AT with 
greater activity than that of either mutation alone.  Site directed mutagenesis was carried 
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out to obtain the double mutant Arg1Met Glu338Ser.  The single mutant Arg1Met was 
used as the parent and the primers for the Glu338Ser were again employed. 
Proteins were expressed for the following variants, pHAR10a (control), pHAR4-p (wild 
type), Arg1Met, Glu338Ser, and Arg1Met Glu338Ser on a 5× 100 mL scale and the 
resulting cell pellets were fractionated in order to obtain the periplasmic fractions as 
before (§ 6.4.5).  The resulting periplasmic fractions were then concentrated using 
Amicon Ultra-15 centrifugal filter units (Millipore™).  Although the use of the filters is 
recommended for the concentration of dilute or pre-purified proteins column eluents, in 
this case they were used before column purification in order to achieve quicker loading 
times.  However, in practise this concentration step did not significantly improve 
column loading times.  The periplasmic proteins were purified by amylose affinity 
chromatography as before then analysed by SDS-PAGE.  Faint bands were observed at 
the expected 51 kDa (40 kDa MBP + 11 kDa α-subunit) and 29 kDa (β-subunit) (gel 
not shown).  Bradford assay to determine the concentrations of the various proteins 
revealed relatively low values, (ranging from 0.144 – 0.244 µg µL-1) especially for the 
double mutant Arg1Met Glu338Ser (0.058 µg µL-1).  Expression of cytoplasmic AT-
MBP from 100 mL of cell culture typically yielded approximately 1.5 µg µL-1 (§ 
Chapter 2). 
The activity of the concentrated and purified AT mutant proteins with respect to the 
formation of Pen G [5] from 6-APA [1] and PANAC [37] was determined as before.  
However, none of the mutant proteins showed any activity.  Proteins with equally low 
concentrations had shown activity in other areas of the work (§ Chapter 2).  The lack of 
activity was presumed to be due to the combination of the long protein purification 
times and the use of the concentrating filters the effects of which were detrimental to the 
protein’s activity.  Although neither of these would be factors in any assay, the low 
yields of protein obtained from the periplasm compared to cytoplasm however did give 
cause for concern.  For this reason as well as the high cost of IPN [18], a library of 
MBP-AT variants was not created nor subsequently screened. 
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3.3 Chapter 3 Summary 
The use of the signal peptide, MBP, to target AT to the periplasm of E. coli was 
reinvestigated in order to allow the development of a life or death selection method for 
the identification of improved hydrolysis activity AT mutants. 
A salt bridge between Met1 and Glu338 had been observed which had implications for 
the fusion of any signal peptide to the N-terminus of AT.  Site directed mutagenesis was 
used to introduce mutations to AT that would compensate for the presence of the signal 
peptide.  The single mutant Arg1Met was made in order to restore the methionine 
removed during the cloning process.  Glu338Ser was made to neutralise the lone 
negative charge that arose due to the presence of the signal peptide.  The double mutant 
Arg1Met Glu338Ser was also made and investigated. 
The mutations did restore activity to AT.  However, the concentration of protein was 
thought to be too low to allow MBP-AT fusions to be employed for the identification of 
improved hydrolysis activity AT mutants. 
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CHAPTER FOUR 
Investigations into β−Lactamase 
Towards an Approach for Hydrolysis 
Screening of AT 
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4.1 Introduction 
As the periplasmic expression of AT had been deemed unsuitable for use as part of a 
selection method for identifying AT mutants with increased activity for the hydrolysis 
of IPN [18], another approach was sought. 
As already discussed (§ Chapter 3), a major problem when considering the hydrolysis 
step independently from the acylation step is that once IPN [18] is hydrolysed, 6-APA 
[1] remains in the active site of AT awaiting re-acylation; 6-APA [1] effectively acts as 
an inhibitor of AT.  One way to overcome this problem would be to somehow remove 
6-APA [1] from the active site of AT thus allowing AT to turn over more molecules of 
IPN [18], the higher concentration of the resulting hydrolysed product would be easier 
to detect in any screening or selection method.  To this end the use of a β-lactamase was 
investigated. 
β-Lactamases are a group of bacterial enzymes that cleave and hydrolyse the β-lactam 
ring of β-lactam antibiotics (§ Scheme 4.1).  They target the bacterial cell wall and are 
responsible for the resistance of bacteria to this class of antibiotic.  Their role in the 
resistance of bacteria to β-lactam antibiotics has already been discussed (§ 1.4.1). 
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Scheme 4.1 Cleavage of a β-lactam by a β-lactamase 
It was hoped that the presence of a β-lactamase during a screen of AT variants would 
hydrolyse 6-APA thus freeing up the active site of AT.  However, the β-lactamase used 
would have to be selective for 6-APA [1] only and not for IPN [18].  If β-lactamase also 
hydrolysed IPN [18] this would lead to the identification of false hits from the screen.  
The survival of colonies screened in the presence of IPN [18] would therefore be due to 
the hydrolysis of IPN [18] by AT and not β-lactamase and any colonies that did survive 
the screen would hopefully contain AT variants with improved capability for the 
hydroysis of IPN [18]. 
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4.1.1 RTEM-1 β-Lactamase 
There are four different classes (A-D) of β-lactamases based on primary sequence 
homology.  Class B β-lactamases are metallo-enzymes that use zinc ions to hydrolyse 
the β-lactam ring, whereas classes A, C and D β-lactamases utilize a catalytic serine as 
the primary nucleophile.  RTEM-1 β-lactamase is a class A enzyme and is the most 
common plasmid-encoded β-lactamase in Gram-negative bacteria (Brown, Shanker et 
al. 2009). 
A more recent classification system where β-lactamases are grouped according to their 
hydrolytic and inhibition properties is also in use in clinical settings.  According to this 
classification system RTEM-1 falls into subgroup 2b.  Subgroup 2b β-lactamases 
readily hydrolyze penicillins and early cephalosporins, such as cephaloridine [34] and 
cephalothin [15], and are strongly inhibited by clavulinic acid [17] and tazobactam [35] 
(Bush and Jacoby 2010).  Unfortunately for the author there is no comparison of the 
susceptibility of the various β-lactamases to 6-APA [1]. 
The nucleotide sequence of the ampicillin resistance gene of Escherichia coli plasmid 
pBR322 (penicillin amide-β-lactamhydrolase EC 3.5.2.6) has been determined 
(Sutcliffe 1978) and in this work the standard numbering scheme for the class A β-
lactamases was employed when referring to the residues of RTEM-1 β-lactamase 
(Ambler, Coulson et al. 1991).  In the case of RTEM-1, the leader sequence is 23 amino 
acids long and numbering starts at three, therefore the first amino acid in the mature 
protein is His26. 
4.1.2 The Natural Selectivity of β-Lactamase for 6-APA 
Initial work on this approach began by looking at the natural selectivity of β-lactamase 
for 6-APA [1].  The commercially available Penicillinase (EC 3.5.2.6) from Bacillus 
cereus β-lactamase (Sigma®) was used.  Solutions (12.3 mM, 1.5 mL) of both 6-APA 
[1] and Penicillin G [5] were incubated with the β-lactamase (2 mg) at 25˚C overnight 
then analysed by 1H NMR.  Control experiments without any β-lactamase were also 
carried out.  Hydrolysis of Penicillin G [5] by β-lactamase was evident as was the 
hydrolysis of 6-APA [1] albeit it lower than that of Penicillin G [5].  Although the 
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results showed that β-lactamase did have some activity for 6-APA [1] the effect on E. 
coli could not be deduced. 
The resistance of E. coli to 6-APA [1] inferred by the presence of β-lactamase was 
determined by plating XL1-Blue cells containing the pHAR10a plasmid, i.e. no β-
lactamase present, and cells containing the pUC18 plasmid  onto various concentrations 
of 6-APA [1].  pUC18 is a commercially available plasmid which contains the ampR 
gene encoding β-lactamase (Sutcliffe 1978).  The MIC of 6-APA [1] for cells with and 
without β-lactamase were 10 mM and 3.5 mM respectively.  This showed that the 
presence of the β-lactamase increased the MIC of the E. coli cells to 6-APA [1] by 
6.5 mM. 
In order to increase the sensitivity of the assay for hydrolysis mutants in the presence of 
β-lactamase the use of the E. coli ESS strain was investigated.  E. coli ESS had been 
used as an indicator strain throughout the project as it had previously been found to be a 
thousand times more sensitive to Penicillin G [5] than XL1-Blue (Derome 2003).  It 
was anticipated that if this E. coli strain could be used in tandem with β-lactamase a 
highly sensitive hydrolysis assay would result. 
In order to clarify the suitability of E. coli ESS as a host organism, competent E. coli 
ESS cells were prepared (§ 6.3.6).  Transformation of both pHAR10a and pUC18 into 
E. coli ESS was then attempted.  Transformation of XL1-Blue cells with both pHAR10a 
and pUC18 was also carried out concurrently as a control experiment.  Unfortunately, 
transfection into E. coli ESS could not be achieved using either heat shock or 
electroporation methods (§ 6.3.4 and § 6.3.5). 
It was not clear why it was not possible to transfect E. coli ESS.  It was thought that it 
might be due to differences in the cell wall structure of E. coli ESS compared to that of 
XL1-Blue.  During transfection the cell wall is temporarily disrupted to allow the 
negatively charged DNA molecules to pass through the cell membrane.  In the case of 
cells with a weaker cell wall, as is supposed in the case of E. coli ESS, this process may 
be detrimental to the cell.  These cell wall differences would also account for the 
increased susceptibility of E. coli ESS to β-lactam antibiotics, which are known to 
inhibit the growth of bacteria by inhibiting cell wall formation (§ 1.3). 
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As E. coli ESS could not be transfected with either pHAR10a or pUC18, other ways to 
increase the sensitivity of the assay were considered.  As had already been shown by 1H 
NMR and MIC determination experiments, β-lactamase could inactivate 6-APA [1] by 
hydrolysis.  However, it was wondered if this could be improved further using directed 
evolution. 
4.2 Directed Evolution of RTEM-1 β-lactamase  
In a well-known example of directed evolution, β-lactamase was used as a model 
system for mutagenic DNA shuffling for molecular evolution.  Repeated cycles of 
shuffling and backcrossing were each followed by selection on increasing 
concentrations of the antibiotic cefotaxime [36] resulting in mutants with an increased 
MIC of 640 µg mL-1, a 32,000-fold increase on wild type (Stemmer 1994).  This work 
shows that the substrate specificity of β-lactamase can be altered using directed 
evolution. 
A β-lactamase that had high selectivity for 6-APA [1] and no selectivity for IPN [18] 
was desired.  By having a high selectivity for 6-APA [1] the sensitivity of the screen 
would be increased as the amount of 6-APA [1] removed from the active site of AT 
would be greater thus allowing AT to turnover more molecules of IPN [18].  If the same 
β-lactamase variant could not hydrolyse IPN [18] any hydrolysis would be due to AT 
present only and not the β-lactamase.  However, it was expected that some hydrolysis of 
IPN [18] by β-lactamase would be inevitable and a mutant with a high specificity for 6-
APA [1] and low specificity for IPN [18] was the goal. 
4.2.1 Random Approach 
4.2.1.1 Strategy 
A random library of β-lactamase variants was generated and screened. Due to the high 
cost of IPN [18] initial screening was carried out in the presence of 6-APA [1] and the 
antibiotics ampicillin [8] and Penicillin G [5].  According to the First law of Directed 
Evolution (‘You get what you screen for’) (Arnold 1998) therefore this was a slightly 
risky strategy especially when the side chains of ampicillin [8], Penicillin G [5] and IPN 
[18] are compared (§ Scheme 4.2).  Ampicillin [8] and Penicillin G [5] have aromatic 
side chains whereas IPN [18] does not.  However, in terms of initial screening this was 
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considered sufficient, as a mutant with no binding capability for any side chain as in the 
case of 6-APA [1] was desired. 
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Ampicillin [8] Penicillin G [5] Isopenicillin N [18]  
Scheme 4.2 Side chains of ampicillin [8], Penicillin G [5] and IPN [18] 
4.2.1.2 Library Generation 
To create a library of β-lactamase mutants the commercially available mutator strain 
XL1-Red (Stratagene) was used (§ 6.3.2).  This method involves propagating the cloned 
gene into XL1-Red, an E. coli strain which is deficient in three of the primary DNA 
repair pathways.  The random mutation rate in this triple mutant is approximately 5000-
fold higher than that of wild type.  The main advantage of this method is that it does not 
require extensive genetic or biochemical manipulation and as such is a rapid method of 
library generation. 
The supplied protocol was carried out as follows.  pUC18 was first transformed into the 
XL1-Red cells using the heat shock method (§ 6.3.4).  After a short incubation period 
(37˚C, 1 hour) the cells were harvested and plated on LB agar supplemented with 
ampicillin (50 mg L-1).  After overnight incubation the resulting colonies were washed 
off the plates with LB media to produce a stock cell culture that was used to inoculate 
LB media containing various concentrations of 6-APA [1] (0, 6, 8, 10 and 12 mM).  
After a period of incubation (18 hours, 37˚C, 250rpm), the OD600 of the cell cultures 
was measured and the results were as shown in Table 4.1. 
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6-APA /mM OD600 
0 1.1340 
6 0.9287 
8 0.4973 
10 0.2757 
12 0.0172 
Table 4.1 To show the OD600 values obtained for transformants grown at various 
  6-APA [1] concentrations. 
As can be seen from the data in the table the cell density of the cultures decreased as the 
concentration of 6-APA [1] increased.  It was anticipated that by growing the 
transformants in the presence of 6-APA [1] and not ampicillin [8] some selection would 
be observed, which would give an indication of the hydrolysis capability of the mutants 
present in the library. 
The DNA was isolated from the harvested cells (§ 6.2.1).  The DNA obtained from the 
cells grown at 8, 10 and 12 mM 6-APA [1] was combined.  The plasmid DNA was 
analysed by agarose gel electrophoresis after single site digest by the restriction 
endonuclease NdeI (§ 6.2.4).  The size of the resulting band (2,686 bp expected) was 
confirmed by comparison to a DNA marker (not shown). 
4.2.1.3 Screening of the Library 
The DNA libraries were transformed into XL1-Blue (§ 6.3.4) and the resulting cells 
plated onto 6-APA [1] (12 and 15 mM).  Cells were also plated onto ampicillin [8] 
(50 mg L-1) LB agar plates.  After a period of incubation (18 hours, 37˚C) colonies were 
seen to have only formed on the ampicillin [8] plates.  Ten of these clones were selected 
and the region containing the ampR gene was sequenced (§ 6.2.5. For primers see 
Appendix D), however no mutations were found.  Mutator strains introduce random 
mutations into the entire plasmid; the mutations introduced are not limited to the gene 
of interest.  As no mutations were found in the ampR gene, which would explain the 
survival of the colonies, it was assumed that mutations in the promotor region were 
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responsible for the survival of these colonies perhaps by increasing the amount of β-
lactamase present in the colonies. 
The non-appearance of mutants on either 12 or 15 mM 6-APA [1] was believed to be 
due to increased sensitivity of the transformants to 6-APA [1].  It had previously been 
found that the MIC of XL1-Blue with pUC18 was 12 mM 6-APA [1] therefore the 
library would be plated onto lower concentrations of 6-APA [1]. 
The library was transformed into XL1-Blue (100 µL) as before and the resulting cells 
plated onto 10 mM 6-APA [1] agar plates (4×22.5×22.5 cm).  This resulted in many 
colonies, which were too numerous to count.  The colonies were washed off the plates 
using liquid media to give a stock cell culture, which was diluted 100-fold then plated 
onto various concentrations of 6-APA [1] (11, 11.5, 12 and 12.5 mM) agar plates 
(6×22.5×22.5 cm).  On the 11, 11.5 and 12 mM plates numerous colonies appeared.  At 
12.5 mM 6-APA [1] 200 colonies were obtained from the approximately ~21,000 
colonies plated at 12.5 mM. 
Of these 60 were picked at random and tooth picked onto agar plates containing either 
ampicillin [8] (50 mg L-1) or 6-APA [1] (12.5, 13, 15 or 20 mM).  Of these 11 colonies 
were killed at 20 mM.  All 60 survived in the presence of ampicillin [8].  These 11 
colonies were sequenced to determine if there was any difference in the ampR gene that 
lead to this result.  However, no mutations were found in the ampR gene. 
The 60 colonies were again tooth picked onto agar plates containing either ampicillin 
[8] (100 mg L-1) or 6-APA [1] (25 mM).  Of these 4 did not survive the higher 
concentration of 6-APA [1] but all survived the higher ampicillin [8] concentrations.  
These 4 were sequenced however the data did not reveal any differences in the ampR 
gene. 
Although the colonies selected so far contained had improved resistance to both 6-APA 
[1] and ampicillin [8], sequencing again revealed no mutations present in the ampR gene 
which would explain the increased resistance.  Clearly the random nature of the library 
generation did not give the desired effect therefore another approach was needed. 
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4.2.2 Rational approach 
As the random approach to mutagenesis of β-lactamase had been unsuccessful a rational 
approach was investigated.  As the goal was to find a mutant with a high specificity for 
6-APA [1] and a low specificity for IPN [18] it was reasoned that the substrate binding 
capabilities of β-lactamase should be targeted and the residues responsible for binding 
the side chain of the β-lactam antibiotics would be of interest. 
In order to identify the residues responsible for binding the side chains of β-lactams a 
crystal structure of β-lactamase was needed with a β-lactam substrate in situ.  Due to 
the clinical importance of β-lactamases and their detrimental effects on β-lactam 
antibiotics much work towards elucidating their structures and determining their 
catalytic mechanism has been carried out and a number of crystal structures have been 
reported at various resolutions (Herzberg and Moult 1987; Knox and Moews 1991; 
Jelsch, Lenfant et al. 1992).  β-lactamase consists of two domains connected by two 
hinge regions.  The first domain consists of a five-stranded β-sheet and the second 
domain is made up of eight helices. 
4.2.2.1 Crystal Structure of RTEM-1 
The X-ray crystal structure of the deacylation-defective mutant (Glu166Asn) of RTEM-
1 β-lactamase with and without Penicillin G [5] at 1.7 Å resolution has been reported 
and compared with that of native RTEM-1 (Strynadka, Adachi et al. 1992).  The mutant 
Glu166Asn had been previously found to be deacylation defective (Adachi, Ohta et al. 
1991).  Accumulation of a covalent complex with Penicillin G [5] occurs and the acyl-
enzyme intermediate obtained has the required stability for crystallographic studies.  
The complex formed consists of Penicillin G [5] trapped by the RTEM-1 Glu166Asn 
mutant via covalent bond between C7 of Penicillin G [5] to Ser 70 Oγ as shown in 
Figure 4.1 below. 
The interactions described below are believed to stabilize the initial binding of 
Penicillin G [5].  There are two hydrogen bonds between the carbonyl oxygen atom O8 
to the main chain nitrogen atoms of Ser70 (2.7 Å) and Ala237 (3.0 Å).  These 
interactions make up the oxyanion binding site of the enzyme.  The nitrogen N14 and 
oxygen O16 atoms of the side chain peptide on Penicillin G [5] form hydrogen bonds 
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with the main chain carbonyl oxygen atom of Ala237 (2.9 Å) and the amide nitrogen of 
Asn132 Nδ2 (2.6 Å) respectively. 
The carboxylate oxygen atoms O12 and O13 of Penicillin G [5] form strong hydrogen 
bonds to the side chain nitrogen atom of Arg244 Nη1 and the side chain oxygen atom of 
Ser235 Oγ.  There is a very weak interaction between the carboxylate carbon atom C3 
and Lys234 Nζ (3.5 Å).  The distance between the Ser130 Oγ and N4 of thiazolidine 
ring of Pen G [5] is 3.1 A.  However, the orientation does not allow a hydrogen bond, in 
which N4 would be the donor atom, only van der Waals interaction. 
A crystal structure of an acylation transition state analog has also been reported which 
goes towards clarifying some of the mechanistic implications (Maveyraud, Pratt et al. 
1998).  The residues directly involved in catalysis are Ser70, Lys73, Ser130 and Glu166 
(carboxylate is the general-base catalyst).  The charged groups on Lys234 and Arg244 
stabilise intermediates and therefore act as electrostatic catalysts.  These residues are 
also shown in Figure 4.1. 
4.2.2.2 Mechanism of catalysis 
There are two stages in the catalytic mechanism of class A β-lactamases.  Acylation 
followed by deacylation.  In the acylation step a proton is removed from Ser70.  The 
resulting oxygen anion of Ser70 then attacks the carbonyl of the β-lactam resulting in an 
acyl-intermediate.  This acyl-intermediate then collapses with the amide nitrogen 
picking up a proton from a coordinated water molecule.  Attack of the acyl-intermediate 
by a water molecule activated by Glu166 and protonation of Ser70 completes the 
hydrolysis of the β-lactam and regenerates the enzyme.  This mechanism is based on the 
acyl-enzyme intermediate shown in Figure 4.1. 
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Figure 4.1 a) An overview of β-lactamase (blue) with Penicillin G [5] in the active 
  site (PDB: 1FQG); b) Catalytic residues of β-lactamase (sticks) in  
  relation to Penicillin G [5] (lines) (PDB: 1FQG); c) Acyl-enzyme  
  intermediate (Strynadka, Adachi et al. 1992). 
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4.2.2.3 Selection of Residues for Mutation 
Residues implicated in the mechanism were not considered for mutation.  However the 
stabilizing residues described above were.  The crystallographic data was downloaded 
from the Protein Data Bank (PDB ID: 1FQG) and viewed using MacPyMOL, a 
molecular viewing system, in order to help select suitable residues for mutation.  Any 
residues that appeared to interact with the side chain of Penicillin G [5] were considered 
while those that interacted with the penam nucleus were not. 
It appeared that Pen G [5] enters β-lactamase via the penam nucleus end first so when 
considering residues to mutate it was wondered whether a molecular sieving approach 
could be affected.  That is to say increasing sterics at pertinent positions would 
effectively block larger molecules from entering β-lactamase so in terms of selecting 6-
APA [1] over Pen G [5], 6-APA [1] would be selected due to its smaller size.  However, 
this may also depend on the substrates used for screening vide supra. 
After much consideration of the β-lactamase structure and its interactions with 
Penicillin G [5] in MacPyMOL, two residues were selected for mutation, Asn132 and 
Ala237. 
 
Figure 4.2 The interaction of Asn132 ans Ala237 with Penicillin G [5] (PDB:  
  1FQG). 
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4.2.2.4 Site Saturation Mutagenesis 
Site saturation mutagenesis (§ 6.3.1) was performed on pUC18 to obtain two separate 
libraries with a range of mutations at Asn132 and Arg237 (for primers see Appendix 
D). 
Transfection of XL1-Blue with the pUC18 libraries and subsequent plating on 8 mM 6-
APA [1] gave approximately 100 colonies per library.  These colonies were tooth 
picked onto agar plates containing 30 mM 6-APA [1], 100 mM Pen G [5] or 100 mM 
ampicillin [8] and incubated (18 hours, 37˚C).  The colonies showed various 
characteristics in terms of resistance to the three substrates. 
4.2.2.5 Screening the Asn132 and Ala237 Libraries 
Potentially there are 8 resistance scenarios depicted in Figure 4.3 below.  Colonies that 
were resistant to the higher 6-APA [1] concentrations and not resistant to Penicillin G 
[5] or ampicillin [8] were desired.  However, as a result of screening colonies with these 
characteristics did not arise.  The colonies certainly had different selectivities compared 
to one another and some were selected for sequence determination in order to try and 
ascertain some clues that would account for these differences. 
 
Figure 4.3 Resistance profile of β-lactamase variants  
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Colonies with resistance profiles 3 and 8 (as shown in Figure 4.3) were selected from 
both libraries as this gave manageable numbers for sequence determination.  The results 
are shown in Table 4.2. 
Resistance 
Profile 
Total No. Library No. Phenotype 
1× N132N N132X 8 
7x wt 
1× A237A 
3 13 
A237X 5 
4× wt 
1× wt N132X 1 
- 
7× A237G 
8 9 
A237X 8 
2× wt 
Table 4.2 Sequencing results for variants obtained from screening Asn132 and 
  A237 libraries 
Of the 21 colonies selected for sequence determination only three contained mutations 
and two of these were silent.  The mutant found was Ala237Gly and was not resistant to 
the higher concentrations of any of the substrates used under the screening conditions.  
Tooth picking experiments to compare the mutant with wild type β-lactamase were 
carried out at various concentrations of 6-APA [1] (10 mM, 20 mM, 30 mM and 40 mM) 
and ampicillin [8] (50 and 100 mg L-1) not used during the screening process, 
unfortunately there was no difference in their resistance, which confirmed the screening 
results. 
When the mutant was considered again in the context of its interaction with Penicillin G 
[5], it was perhaps not surprising that this mutation had no effect on the substrate 
specificity of the mutant as it is the main chain nitrogen and oxygen atoms of Ala237 
that interact with Penicillin G [5] via the carbonyl oxygen O8 and the nitrogen N14 
respectively; substituting an alanine for a glycine residue was not sufficient to alter the 
interaction as desired. 
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Despite repeated attempts at the screening process, no key mutations towards the goal 
of increased 6-APA [1] activity and reduced acylated penicillins were obtained from 
either the Asn132 or Ala237 libraries.  This was disappointing as the rational approach 
made possible by the crystallographic data augured well. 
When the amino acid sequences for various class A β-lactamases (Ambler, Coulson et 
al. 1991) were compared it was observed that at position 132 Asn is conserved through 
all 20 examples.  This would suggest that this is a key residue.  In the case of position 
237, Ala dominated (×11) however Gly was also present (×4) as well as Glu (×2), Thr 
(×2) and Ser (×1), which would perhaps suggest that this position is not as crucial.  The 
mutant Ala237Gly identified from the screening process was therefore homologous. 
Further literature searches revealed that Asn132 is in fact a key residue in binding the 
side chain of β-lactam antibiotics.  In one study each residue of RTEM-1 β-lactamase 
was mutagenised in order to identify those that are essential to its structure and function.  
43 out of the 263 amino acid residues were determined to be essential.  Asn132 
belonged to a sub group of these essential residues that were believed to make important 
interactions for substrate binding or active site conformation (Huang, Petrosino et al. 
1996). 
In another study, conserved β-lactamase active site residues were mutated and screened 
on ampicillin [8], which led to the identification of Asn132Asp.  This mutant was found 
to have a decreased kcat for Penicillin G [5] and ampicillin [8] but an increased kcat for 6-
APA [1] (Osuna, Viadiu et al. 1995). 
4.2.2.6 Generation of Asn132Asp  
Site directed mutagenesis (§ 6.3.1) was carried out in order to create the β-lactamase 
mutant Asn132Asp described in the literature vide supra (for primers see Appendix D).  
Subsequent sequencing (§ 6.2.5) of the isolated DNA (§ 6.2.1) confirmed the mutation 
had been introduced.  Protein was expressed (§ 6.4.2) and the harvested cells were lysed 
in order to obtain the periplasmic fraction (§ 6.4.5).  Ala237Gly was also prepared.  The 
proteins were not purified and were used as crude extracts. 
The abilities of Asn132Asp and Ala237Gly to hydrolyse 6-APA [1], Penicillin G [5] 
and ampicillin [8] were compared by 1H NMR as follows. 
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Prior to use in these 1H NMR experiments, 6-APA [1] was purified by dissolution in 
water (1 g per 40 mL) using the minimum amount of sodium bicarbonate and re-
precipitated by addition of hydrochloric acid to pH 4.5.  The resulting precipitate was 
filtered and dried.  It had been found that a small impurity present in commercial 
sources of 6-APA [1] had an inhibitory effect on class C β-lactamases (Pratt, Dryjanski 
et al. 1996). 
Each substrate was dissolved in 0.1 M phosphate buffer (10 mg mL-1), which was 
divided into 1 mL aliquots.  β-lactamase (100 µL) was then added to the substrate 
solution.  The control aliquot contained no enzyme but had the equivalent volume of 
phosphate buffer (0.1 M, 100 µL) added.  After a period of incubation (1 hour, 37˚C, 
250rpm) the samples were quenched with methanol (100 µL), filtered through cotton 
wool then lyophilised.  1H NMR analysis was carried out in D2O. 
The degree of hydrolysis was calculated by determining the ratios in the 1H NMR 
spectrum based on the peaks corresponding to the C-H’s of the β-lactam ring.  It should 
also be noted that the resulting hydrolysis products can epimerize and this was taken 
into account when the ratios were calculated. 
Experiments to investigate the hydrolysis of ampicillin [8] with Ala237Gly were carried 
out.  It was found that complete hydrolysis of ampicillin [8] occurred in the presence of 
wild type β-lactamase, however there was only partial hydrolysis with Ala237Gly 
(~80%).  Partial hydrolysis also occurred with no β-lactamase (~5%). 
This result was encouraging.  Although previous MIC experiments had shown no 
difference between wild type and Ala237Gly for 6-APA [1], Penicillin G [5] or 
ampicillin [8], this showed that the mutation did have some effect on the hydrolysis of 
Penicillin G [5] albeit small and perhaps in combination with other mutations this could 
be improved. 
Next, the hydrolysis of 6-APA [1], Penicillin G [5] and ampicillin [8] with Asn132Asp 
was investigated the results of which are summarized in the Table 4.3.  It can be seen 
that compared to wild type, Asn132Asp has a similar ability to hydrolyse 6-APA [1] but 
a reduced ability for the hydrolysis of Penicillin G [5] and ampicillin [8]. 
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Substrate 
6-APA Penicillin G Ampicillin 
β-lactamase 
SM/% HP/% SM/% HP/% SM/% HP/% 
Wild type 33 67 23 77 16 84 
Asn132Asp 44 56 88 12 89 11 
None 90 10 <100 <1 <100 <1 
SM Starting material  HP Hydrolysed Products 
Table 4.3 To show the hydrolysis of various substrates with Asn132Asp 
 
These results were promising and it was wondered whether this substrate specific 
hydrolysis ability could be improved further.  Ideally a mutant that can only hydrolyse 
6-APA [1] and not IPN [18] was the goal however a mutant with as large a difference in 
its hyrolysing ability between the two substrates would also be useful.  It was decided to 
combine the Asn132Asp and Ala237Asp mutations and study their combined effects. 
4.2.2.7 Generation of Asn132Asp Ala237Gly 
The Asn132Asp mutation was introduced into Ala237Gly using site directed 
mutagenesis (§ 6.3.1.  For primers see Appendix D).  Subsequent sequencing (§ 6.2.5) 
of the isolated DNA (§ 6.2.1) confirmed the mutation had been introduced.  Protein was 
expressed (§ 6.4.2) and the harvested cells were lysed in order to obtain the periplasmic 
fraction (§ 6.4.5).  Wild type β-lactamase and the single mutants Asn132Asp and 
Ala237Gly were also prepared as before. 
The hydrolytic capability of the mutants was determined by 1H NMR as described 
above and the results are shown in Table 4.4 below.  It can be seen that the single 
mutant Asn132Asp has the greatest difference between its ability to hydrolyse 6-APA 
[1] and Penicillin G [5] and ampicillin [8].  The single mutant Ala237Gly and the 
double mutant Asn132Asp Ala237Gly have comparable activities and the difference in 
their ability to hydrolyse 6-APA [1] over Pencillin G [5] or ampicillin [8] is not as great 
as that shown for Asn132Asp. 
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Substrate 
6-APA Penicillin G Ampicillin 
β-lactamase 
SM/% HP/% SM/% HP/% SM/% HP/% 
Wild type 20 80 46 54 44 56 
Asn132Asp 13 87 95 5 91 9 
Ala237Gly 68 32 76 24 57 43 
Asn132Asp Ala237Gly 51 49 77 23 56 44 
None 100 0 100 0 94 6 
SM Starting material  HP Hydrolysed Products 
Table 4.4 To show the hydrolysis of various substrates with β-lactamase variants 
These 1H NMR experiments were useful for quantifying the hydrolytic capability of the 
various mutants compared to wild type β-lactamase.  However, it was not known how 
the mutants would affect the resistance of the corresponding colonies present in any 
screening or selection method.  Therefore, experiments to determine the resistance of 
the various mutants in XL1-Blue were carried out. 
Colonies were streaked onto agar plates containing the various substrates at various 
concentrations.  After a period of incubation (37˚C, 18 hours) the surviving colonies 
were noted.  In terms of colony resistance, there was no difference between the single or 
double mutants.  Compared to wild type β-lactamase they had the same resistance to 6-
APA [1] more importantly however was the single and double mutants decreased 
colony resistance to the β-lactams, Penicillin G [5] and ampicillin [8].  The results are 
shown in Table 4.5 below. 
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Substrate Wild type Asn132Asp Ala237Gly Asn132Asp Ala237Gly 
10 mM 6-APA Y Y Y Y 
20 mM 6-APA N N N N 
30 mM Pen G Y N N N 
50 mM Pen G N N N N 
60 mM Pen G N N N N 
50 mM Amp Y N N N 
Table 4.5 To show colony survival with various β-lactams 
It was also decided to compare the hydrolysis of mixtures of the substrates as in any 
assay a mixture of acylated and un-acylated 6-APA [1] would be present.  This was 
done for the Asn132Asp mutant only as this mutant so far had given the most promising 
results. 
1H NMR experiments were set up as before containing 50:50 mixtures of 6-APA [1] 
plus either Penicillin G [5] or ampicillin [8].  The reactions were followed over one 
hour with samples taken for analysis by 1H NMR every ten minutes.  Due to the 
complex mixtures obtained it was necessary to spike the samples with partially 
hydrolysed substrates in order to correctly identify the relevant peaks in the NMR 
spectra obtained.  For both the Penicillin G [5] and ampicillin [8] experiments, β-
lactamase seemed to preferentially hydrolyse the acylated 6-APA over 6-APA [1]. 
Some example 1H NMR spectra for the above experiments are shown in Appendix G. 
At this point it was decided to use Asn132Asp and Ala237Gly as starting points for the 
creation of a new library of β-lactamase variants.  Although the results so far show that 
these mutants alone do show improved hydrolysis of 6-APA [1] compared to wild type. 
However, it was hoped that this could be improved further with additional mutations.  
Also a mutant with reduced hydrolytic capability for acylated 6-APA [1] was desired so 
that when both substrates were present 6-APA [1] would be preferentially hydrolysed.  
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To this end another random library was desired. 
4.2.3 Random Library with Rational Mutants  
As has been demonstrated random mutation using a mutator strain although a quick way 
to generate random mutant libraries it was unsuccessful in our case in leading to the 
identification of suitable β-lactamase mutants.  The lack of β-lactamase mutants from 
using the mutator strain was believed to be due to the fact that mutations were 
introduced randomly into the entire plasmid and were not restricted to the β-lactamase 
gene alone.  It was desired that mutations would only be present in the gene of interest 
therefore the use of the commercially available error prone PCR kit GeneMorph® II 
Random Mutagenesis (Stratagene) was investigated.  Another advantage of using this 
kit is that useful mutation rates with minimal mutational bias are achieved.  Also, by 
varying the amount of DNA used the number of mutations introduced can be controlled.  
In our case this was important as it was believed only minor mutation of the single 
mutants Asn132Asp and Ala237Gly was required in order to optimize their selectivity 
for 6-APA [1] over IPN [18] or other penicillins. 
4.2.3.1 Strategy 
The strategy for library creation was to carry out error prone PCR according to the 
supplied protocol (§ 6.3.3).  Restriction digest of the resulting PCR product would give 
the β-lactamase gene fragment, which would then be ligated back into the pUC18 
plasmid backbone.  The pUC18 backbone would be obtained by digestion using the 
same restriction enzymes used to obtain the gene fragment, which would allow the 
backbone and the gene fragment to be ligated without further manipulation. 
4.2.3.2 Choice of Restriction Enzymes 
Suitable restriction enzymes to isolate both the gene fragment from pUC18 and the 
pUC18 backbone were selected using Vector NTI® software available from Invitrogen.  
SspI digests at 186 bp and AlwNI digests at 1468 bp of pUC18.  This would result in 
gene fragments of 1282 bp containing the gene fragment and the backbone of 1404 bp.  
These fragments are very similar in size, which would make it difficult to excise them 
from agarose gel after the gel electrophoresis that would be carried out to separate them.  
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Therefore other enzymes were selected in order to singly digest the undesired fragment 
in each case.   
For the gene fragment XbaI was selected.  This digests the backbone at 2260 bp.  
Digestion of the mutagenised pUC18 with AlwNI, XbaI and SspI would result in the 
desired gene fragment 1282 bp plus two smaller fragments of 792 and 610 bp (Figure 
4.4). 
 
Figure 4.4 Proposed restriction digest of pUC18 to obtain gene fragment 
In order to obtain the backbone, ScaI would be used which digests the β-lactamase gene 
at 508 bp.  Digestion with AlwNI, SspI and ScaI would result in the desired backbone 
1404 bp plus two smaller fragments of 324 and 960 bp.  These smaller fragments would 
be easily separable from the desired fragment in any agarose gel (Figure 4.5) 
 
Figure 4.5 Proposed restriction digest of pUC18 to obtain backbone 
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4.2.3.3 Creation of the Library 
Error prone PCR was carried out according to the supplied protocol using a mixture of 
Asn132Asp, Ala237Gly and Asn132Asp Ala237Gly (20:1:1) pUC18 plasmid was used 
as the starting point for library generation (for primers see Appendix D).  The quantity 
of DNA added was calculated from Table 4.6.  As the β-lactamase gene is 857 bp and 
the pUC18 plasmid is 2686 bp long, 1550 ng was added in order to obtain a low to 
medium mutation rate library. 
Mutation rate Mutation 
frequency 
(mutations/ kb) 
Initial target 
amount (ng)* 
Recommended 
fold amplification 
Low 0-4.5 500-1000 1.5-10 
Medium 4.5-9 100-500 10-100 
High 9-16 0.1-100 100-10,000 
*Not the total amount of template to add but amount of target to amplify. 
Table 4.6 To show the quantity of DNA required for various mutation rates 
The success of the reaction was determined by quantifying the resulting PCR plasmid 
product by agarose gel electrophoresis (§).  Optimization of the PCR conditions was 
required and a PCR cycle of 95 ˚C for 2 minutes; 30 cycles of (95 ˚C, 1 min; 60 ˚C, 
1 min; 72 ˚C, 1 min) 72 ˚C, 10 min; 4 ˚C, 5 min was eventually employed.  These 
conditions gave a satisfactory yield of PCR product.  At this point work ceased due to 
the completion of this PhD study. 
4.3 Chapter 4 Summary 
The mutagenesis of β-lactamase RTEM-1 for use in a hydrolysis screen for AT 
hydrolysis mutants was investigated.  A mutant with high selectivity for 6-APA [1] and 
no selectivity for IPN [18] or other penicillins was desired.  A random library of 
mutants was created using a mutator strain.  However subsequent screening of the 
library did not lead to the identification of any suitable mutants.  A rational approach 
using the X-ray crystal structure of the deacylation-defective mutant Glu166Asn of 
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RTEM-1 β-lactamase lead to the selection of two residues for mutation, Asn132 and 
Ala237.  Site saturation libraries were created and screened which lead to the 
identification of the mutant Ala237Gly.  Further literature searching revealed the mutant 
Asn132Asp to also be suitable for our purposes.  The selectivity of these mutants and 
their double Asn132Asp Ala237Gly for 6-APA [1] and other penicillins were studied by 
1H NMR.  They had the desired selectivity however we hoped to improve this further in 
our labs by combining with other random mutations. 
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CHAPTER FIVE 
 
Equipment & Materials 
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5.1 Suppliers 
The required reagents were generally obtained from Sigma Aldrich® with the following 
exceptions. 
Tryptone was purchased from Oxoid.  Glycerol for bacterial stocks was obtained from 
BDH.  Lyophilised DNase I was supplied by Roche.  The amylose resin used for MBP 
affinity chromatography was supplied by New England Biolabs® Inc. (NEB). 
SDS-PAGE (§ 6.4.8) reagents (40% acrylamide/Bis solution (37.5:1), N,N,N',N'-
tetramethyl-ethane-1,2-diamine (TEMED) and ammonium persulfate) were purchased 
from Bio-Rad.  Protein marker, Broad Range (2-212 kDa) was obtained from NEB. 
Custom oligonucleotides required for PCR experiments were obtained from Invitrogen.  
The nucleic acid co-precipitant GlycoBlue™ was purchased from Applied Biosystems. 
Our industrial sponsors, DSM, kindly supplied AdiPeN [26], 7-ADCA [11], 7-ACA [4]. 
5.2 Equipment 
Sterilisation of equipment and non-thermolabile solutions was carried out by 
autoclaving at 121 ˚C for 20 minutes with a Midas 40 benchtop compact PriorClave. 
The incubators used were either a Haraeus Instrument 6000 Incubator, a Jencons –PLS 
Lab Line Series incubator shaker or a SI 50 Stuart Scientific Orbital incubator.  For 
gentle shaking at RT, an IKA-VIBRAX-VXR orbital shaker was used. 
Centrifugation was carried out using a Beckman Microfuge® Lite benchtop 
Microcentrifuge (<1.5 mL) or a Beckman Allegra™ 21R with a S4180 rotor (up to 
50 mL). 
UV absorbance measurements were carried out using a Beckman DU® 650 
spectrometer. 
pH was measured using a Russell RL 150 pH meter. 
For PCR an MIC Research Inc., PTC-100™ Programmable Thermal Controller was 
used. 
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Milli-Q H2O was obtained using the Millipore Elix S Milli-Q System.  De-ionised water 
undergoes reverse osmosis via Progard™ pack to give water with a resistivity of 
18 MW cm. 
Gels were visualized on a Bio-Rad Gel DOC 2000 UV Transilluminator. 
Proton nuclear magnetic resonance (1H NMR) spectra and carbon nuclear magnetic 
resonance (13C NMR) spectra were recorded on a Varian Unity INOVA 300E 
(300 MHz) or a Varian UNITY 500 (500 MHz) NMR spectrometer.  Chemical shifts, 
δH, are quoted in parts per million (ppm) downfield from tetramethylsilane.  Signal 
splitting patterns are described as singlet (s), doublet (d), triplet (t), quartet (q), quintet 
(qn), sextet (sx), septet (sp), multiplet (m) or broad singlet (brs).  Coupling constants (J) 
are given in Hertz (Hz) to nearest 0.1Hz. 
Fourier Transform Infrared Spectra (FTIR) were recorded on an AT1 Mattson Genesis 
series FTIR spectrometer, with the sample as a KBr disc, a nujol mull, a film, or a 
solution in chloroform.  Selected absorptions are reported and are quoted in 
wavenumbers (cm-1). 
Low resolution mass spectra were recorded on a Micromass Trio 2000 for electron 
ionisation and chemical ionisation conditions, and a Micromass Platform for positive 
and negative ion electrospray analysis. 
Melting points were recorded using a Sanyo Gallenkamp variable heater and are quoted 
to the nearest centigrade. 
Fourier Transform Infrared Spectra (FTIR) were recorded on an AT1 Mattson Genesis 
series FTIR spectrometer, with the sample as a KBr disc, a nujol mull, a film, or a 
solution in chloroform.  Selected absorptions are reported and are quoted in 
wavenumbers (cm-1). 
Low resolution mass spectra were recorded on a Micromass Trio 2000 for electron 
ionisation and chemical ionisation conditions, and a Micromass Platform for positive 
and negative ion electrospray analysis. 
Melting points were recorded using a Sanyo Gallenkamp variable heater and are quoted 
to the nearest centigrade. 
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5.3 Media/Buffers/Reagents 
5.3.1 Microbiological Growth Media 
5.3.1.1 2× YT Medium  
Per 1 L Milli-Q H2O: 
 16 g  Tryptone 
 10 g  Yeast Extract 
  5 g  NaCl 
 (15 g  Bacteriological Agar - for solid media) 
Autoclaved at 121 ˚C for 20 minutes. 
5.3.1.2 LB Medium 
Per 1 L Milli-Q H2O: 
 10 g  Tryptone 
  5 g  Yeast Extract 
  10 g  NaCl 
 (15 g  Bacteriological Agar - for solid media) 
Autoclaved at 121 ˚C for 20 minutes. 
5.3.1.3 Glycerol Stocks 
Per colony: 
 750 µL 50:50 Glycerol: Milli-Q H2O (0.22 µm filter sterilized)  
 750 µL 2× YT supplemented with appropriate antibiotic 
Stored at -80˚C. 
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5.3.2 Antibiotic Stock Solutions 
5.3.2.1 Chloramphenicol 
 30 mg  Chloramphenicol/mL abs. EtOH 
Aliquots (1 mL) stored at -20˚C.  Added to media/agar at T<50˚C.  Used at a final 
concentration of 30 µg mL-1. 
5.3.2.2 Ampicillin 
 50 mg  Ampicillin/mL Milli-Q H2O 
Filter sterilized.  Single use aliquots (1 mL) stored at -20 ˚C.  Added to media/agar at 
<50 ˚C.  Used at final concentrations of 50 and 100 mg L-1. 
5.3.3 Agarose Gel Electrophoresis Reagents 
5.3.3.1 Agarose 
Agarose was suspended in 1× TBE then microwaved until molten.  The resulting liquid 
was poured into casts at T<60˚C and allowed to cool at RT.  See Table 5.1 for agarose 
concentrations used. 
Agarose concentration/%w/v DNA size/bp 
0.5 1,000-30,000 
0.7 800-12,000 
1.0 500-10,000 
1.2 400-7,000 
1.5 200-3,000 
2.0 50-2,000 
Table 5.1 To show agarose concentration required for analysis of DNA 
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5.3.3.2 1× TBE  
 90 mM  Tris base 
 90 mM  Boric acid 
 2 mM  EDTA 
 0.5 µg mL-1 Ethidium bromide 
5.3.3.3 6× BJ Agarose Gel Sample Loading Buffer 
 30%(v/v) Glycerol 
 20 mM  EDTA 
 0.2% (w/v) Bromophenol Blue 
5.3.3.4 1 kb DNA Ladder Solution 
The 1kb DNA ladder was purchased from Gibco-BRL and diluted as shown below. 
 60 µL  1 kb DNA Ladder 
 167 µL 6× BJ 
 100 µL 0.2M NaCl 
 673 µL Milli-Q H2O 
Stored at -20 ˚C.   
5.3.3.5 Restriction Endonuclease Buffers 
NEB provides a colour coded 10× NEBuffer with each restriction endonuclease to 
ensure optimal (100%) activity. (§ Table 5.2 for buffer composition).  Some restriction 
endonucleases require BSA at a final concentration of 100 mg mL-1, which is supplied 
as a 10 mg mL-1 (100×) stock. 
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Buffer No. Colour Composition 
1 Yellow 10 mM Bis Tris Propane-HCl, 10 mM MgCl2, 
1 mM DTT, pH 7.0 at 25˚C. 
2 Blue 50 mM NaCl, 10 mM Tris-HCl, 10 mM MgCl2, 
1 mM DTT, pH 7.9 at 25˚C. 
3 Red 100 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl2, 
1 mM DTT, pH 7.9 at 25˚C. 
4 Green 50 mM Potassium acetate, 20 mM Tris-acetate, 
10 mM Magnesium acetate, 1 mM DTT, pH 7.9 
at 25˚C. 
BSA Storage 
Buffer 
N/A 20 mM Potassium phosphate, 50 mM NaCl, 
0.1 mM EDTA, 5% Glycerol, pH 7.0 at 25˚C. 
Table 5.2 To show NEBuffer composition 
5.3.4 Solutions for the Preparation and Recovery of Competent Cells 
5.3.4.1 TFB1 
The following stock solutions were prepared: 
 3M KOAc   Filter sterilised 
 1M CaCl2  Autoclaved at 121 ˚C for 20 minutes 
 0.5M MnCl2  Autoclaved at 121 ˚C for 20 minutes 
 1M RbCl  Autoclaved at 121 ˚C for 20 minutes 
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100 mL buffer contained: 
 1 mL 3 M KOAc (30 mM final)  
 1 mL 1 M CaCl2 (10 mM final) 
 10 mL 0.5 M MnCl2 (50 mM final) 
 10 mL 1 M RbCl (100 mM final) 
 15 mL Glycerol (15% final) 
Adjusted from pH 6.8 to pH 7.4 using 1M acetic acid (100 µL).  Filter sterilised and 
stored at 4 ˚C. 
5.3.4.2 TFB2 
The following stock solutions were prepared: 
 1M KOH 
 0.75M CaCl2  Autoclaved at 121 ˚C for 20 minutes. 
 1 M MOPS  Adjusted from pH 3.3 to pH 6.5 using 1M   
    KOH (16 mL).  Filter sterilised and stored at RT. 
10 mL buffer contained: 
 0.1 mL 1M MOPS pH 6.5 (10 mM final)  
 1 mL 0.75M CaCl2 (0.75 mM final) 
 0.1 mL 1M RbCl (10 mM final) 
 1.5 mL Glycerol (15% final) 
Adjusted from pH 6.04 to pH 6.5 using 1M KOH (20 µL).  Filter sterilised and stored at 
4 ˚C. 
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5.3.4.3 SOB 
Per 1 L Milli-Q H2O: 
 20 g  Tryptone 
 5 g  Yeast Extract 
 0.5 g  NaCl 
Autoclaved at 121 ˚C for 20 minutes. 
5.3.4.4 SOC 
Per 10 mL SOB (§ 5.3.4.3): 
 200 µL 20%w/v Glucose monohydrate (filter sterilised) 
 100 µL 1M MgCl2 (filter sterilised) 
 100 µL 1 M MgSO4 (filter sterilised) 
Prepared and incubated at 37 ˚C for 1 h immediately before use.  
5.3.5 Solutions for the Preparation of Soluble Proteins from E. coli 
5.3.5.1 Lysis Buffer 
Per 10 mL of column buffer (§ 5.3.6.1): 
 3 mg  EDTA 
 5 mg  Lyophilized Lysozyme 
 1 mg  Lyophilized DNase I 
Prepared immediately before use.   
 111 
5.3.5.2 Spheroplast buffer 
 50 mM  Tris Base  
 5 mM  Dithiothreitol  
Adjusted to pH 8.0 using dilute HCl (aq) then sucrose (20%w/v) was added.  Prepared 
immediately before use. 
5.3.5.3 TD buffer 
 50 mM  Tris Base  
 5 mM  Dithiothreitol  
Adjusted to pH 8.0 using dilute HCl (aq).  Prepared immediately before use. 
5.3.6 Solutions for the Purification of Maltose-Binding Protein Fusions 
5.3.6.1 Column Buffer 
 50 mM  Tris Base  
 5 mM  Dithiothreitol  
Adjusted to pH 7.4 using dilute HCl (aq).  Stored at 4 ˚C. 
5.3.6.2 Elution Buffer 
Column buffer (§ 5.3.6.1) containing: 
 10 mM  Maltose 
Prepared immediately before use. 
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5.3.7 Solutions for Protein Analysis 
5.3.7.1 Bradford Reagent 
 0.01% w/v  Coomassie Blue G250 
 5% v/v  Ethanol (95%) 
 8.5% v/v Phosphoric Acid 
Filtered.  Stored at RT, away from sunlight. 
5.3.7.2 HEPES Buffer 
 50 mM  HEPES 
Adjusted to pH 7.4 using dilute NaOH (aq) then sterilized by filtration through a 45 µm 
membrane.  Stored at 4 ˚C. 
5.3.8 SDS-PAGE Buffers and Solutions 
5.3.8.1 4× Stacking Buffer 
Tris base (60 g, 0.5M) was dissolved in Milli-Q H2O (800 mL) and the pH adjusted to 
6.8 using dilute HCl(aq).  The resulting solution was diluted to 1 L and filtered sterilized 
through a 0.45 µm membrane.  Sodium dodecyl sulphate (4 g, 14 mM) was then added. 
Stored at 4 ˚C. 
5.3.8.2 Stacking Gel  
For two gels the following quantity was prepared: 
3.05 mL Milli-Q H2O 
0.65 mL 40% Acrylamide/Bis solution (37.5:1) 
1.25 mL 4× Stacking buffer 
37 µL 10% w/v Ammonium persulphate 
7 µL TEMED 
Used immediately. 
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5.3.8.3 4× Separating Buffer 
Tris base (181.5 g, 1.9 M) is dissolved in Milli-Q H2O (800 mL) and the pH adjusted to 
8.8 using dilute HCl (aq).  The resulting solution is diluted to 1 L and filter sterilized 
through a 0.45 µm membrane.  Sodium dodecyl sulphate (4 g, 14 mM) was then added. 
Stored at 4 ˚C. 
5.3.8.4 Separating Gel (10% acrylamide) 
For two gels the following quantity was prepared: 
 6.25 mL Milli-Q H2O 
 5.0 mL 40% Acrylamide/Bis solution (37.5:1) 
 3.75 mL 4× Separating buffer 
 5 µL  10% w/v Ammonium persulphate 
 15 µL  TEMED 
Used immediately. 
5.3.8.5 5× SDS-PAGE Running Buffer 
 0.12M  Tris base 
 0.96M  Glycine 
 17 mM  Sodium dodecyl sulphate (SDS) 
Stored at 4 ˚C.  Diluted with Milli-Q H2O and used as 1× solution. 
5.3.8.6 1× SDS/DTT Loading Buffer 
Made using the commercially available (NEB) blue loading buffer pack.  The supplied 
3× loading buffer and 30× reducing agent are mixed in a 9:1 ratio.  For composition see 
Table 5.3 
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3× Loading Buffer 187.5 mM Tris-HCl, 6%w/v SDS, 30% Glycerol, 
0.03%w/v Bromphenol blue. 
 
30× Reducing Agent 1.25 mM DTT 
 
Table 5.3 To show composition of loading buffer and reducing agent (NEB) 
5.3.8.7 Coomassie Blue Stain Solution 
 0.25 g Coomassie Brilliant Blue R250 
 90 mL MeOH:H20 (1:1 v/v) 
 10 mL Glacial AcOH 
Passed through filter paper.  Stored at RT in a brown bottle.  Reusable. 
5.3.8.8 Coomassie Blue Destain Solution 
 500 mL Ethanol 
 200 mL Glacial AcOH 
Diluted to 2 L with H2O.  Stored at RT. 
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CHAPTER SIX 
 
General Techniques 
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6.1 General Information 
Unless stated otherwise the reagents and procedures detailed below are based on those 
contained in Molecular Cloning, A Laboratory Manual, 3rd ed, by Sambrook J. and 
Russell D. W. 
 
6.2 DNA Preparation and Analysis 
6.2.1 DNA Isolation Using QIAGEN’s QIAprep® Miniprep Kit 
Glycerol stocks were streaked onto 2× YT agar (1.5%) plates supplemented with the 
appropriate antibiotic and incubated (37 ˚C, 24 hours).  A single colony was tooth-
picked into 2× YT (5 mL) supplemented with the appropriate antibiotic and incubated 
(27 ˚C, 24 hours).  The resulting cell culture (3 mL) was centrifuged (14000rpm, RT, 
5 min). 
The DNA was isolated and purified from the resulting cell pellet using QIAGEN’s 
QIAprep® Miniprep kit according to the supplied protocol.  The procedure is based on 
the alkaline lysis of bacterial cells.  The DNA in the resulting lysate is selectively 
adsorbed onto the silica membrane of the supplied columns in the presence of a high-
salt buffer, followed by elution with a low-salt buffer or H2O.  This procedure typically 
yielded ~35-45 µL of 150 ng µL-1 DNA solution.  The resulting DNA solution was 
stored at -20 ˚C. 
 
6.2.2 Quantification of DNA by Absorbance at OD260 
The concentration of DNA can be determined by absorbance at 260 nm.  However, only 
purified samples can be quantified in this way as impurities, including DNA, RNA, 
EDTA and phenol, can absorb at this wavelength hence greatly affect the reading. 
An OD260 reading of 1 corresponds to ~33 µg mL-1 of single stranded oligonucleotide, 
and ~40 µg mL-1 and ~50 µg mL-1 of ssDNA and dsDNA respectively. 
The OD260:OD280 ratio indicated the purity of the DNA sample, with values of 1.8 
indicating pure samples.  Samples with values less than this were re-purified. 
 117 
DNA samples were diluted in Milli-Q H2O (1:20) and their OD260 determined using a 
quartz cuvette.  Milli-Q H2O was used as a blank. 
 
6.2.3 Quantification of DNA by Agarose Gel Electrophoresis 
Horizontal agarose gel electrophoresis was performed using Mini-Sub cell GT 
electrophoresis tanks (Bio-Rad).  Gels were cast according to the manufacturer’s (Bio-
Rad) instructions as follows.  Agarose (§ 5.3.3.1 for concentrations used) was 
microwaved until molten then allowed to cool to T<60 ˚C before pouring into the cast.  
The gel was allowed to set at RT for approximately one hour.  The gel assembly was 
then placed in the electrophoresis tank and 1× TBE buffer added to the tank.  6× BJ 
(4 µL) was added to the DNA samples, which were then loaded into the wells using a 
pipette.  The DNA samples were linearised by restriction endonuclease digest (§ 6.2.4) 
prior to electrophoresis.  A range of quantities of 1.1kb DNA standard (20 ng µL-1, 
Stratagene) with 6× BJ (4 µL) were loaded.  A DNA ladder (20 µL, 60 ng µL-1) was 
also loaded.  The tank was then connected to a power pack and a voltage applied to the 
gel. Gels were typically run at 100V for 20 min or until the blue dye reached the front of 
the gel.  Gels were visualised using a UV Transilluminator - UV light setting.  The 
quantity of DNA in the sample(s) was determined by comparison with the DNA 
standard. 
 
6.2.4 DNA Characterisation by Restriction Endonuclease Digest 
Diagnostic cuts of DNA were carried out using restriction endonucleases supplied by 
NEB.  Double digests were also carried out; the compatibility of the endonucleases and 
appropriate buffer were verified online at www.neb.com.  Reaction mixtures typically 
contained the following: 
 3 µL DNA (∼100 ng µL-1) 
 2 µL 10× Buffer (supplied with enzyme) 
 0.5 µL Enzyme 
 15 µL Milli-Q H2O 
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The components were mixed using a pipette prior to addition of the enzyme.  The 
resulting mixture was incubated (37 ˚C, 1 h).  6× BJ (4 µL) was added to the reaction 
mixture prior to analysis by agarose gel electrophoresis (§ 6.2.3) (all 24 µL was loaded 
onto the gel).  A DNA ladder (20 µL, 60 ng µL-1) was also loaded.  The gels were run at 
50V for 90 min. These conditions allowed optimal resolution of the DNA bands in the 
ladder enabling comparison with those of the DNA sample. 
 
6.2.5 DNA Sequence Determination 
Samples were prepared for DNA sequencing using the commercially available 
BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) as follows. 
Reaction mixtures were prepared containing: 
 
 4 µL DNA (100 ng µL-1) 
 1 µL BigDye® v3.1 
 3.5 µL 5× Sequencing Buffer 
 2 µL Primer – sense/antisense (diluted to 20 µM with elution buffer) 
 9.5 µL Milli-Q H2O 
 
The samples were mixed with a pipette before placing on a thermal cycler.  A program 
of [96 ˚C, 2 min; 30× (96 ˚C, 40 s; 50 ˚C, 15 s; 60 ˚C, 4 min); 4 ˚C, 5 min] was used.  
The resulting PCR products were purified by ethanol precipitation (§ 6.2.6).  
Sequencing was performed using an ABI 377 automated sequencer or an ABI 3100 
sequencer.  The results were analysed using Vector NTI Advance™ software. 
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6.2.6 Purification of DNA by Ethanol Precipitation 
DNA solutions were added to a mixture of the following:  
 
 2 µL 3M NaOAc (aq.) pH 5.2 
 2 µL 125 mM EDTA (aq.) pH 8.0 
 50 µL EtOH (absolute) 
 
GlycoBlue™ (0.5 µL) was also added as a co-precipitant during the preparation of 
samples for DNA sequencing (§ 6.2.5).  The resulting mixture was left to stand at RT 
for 10 min, then centrifuged (14000rpm, RT, 30 min) and the supernatant carefully 
decanted using a pipette.  Ethanol (70%, 250 µL) was added and the sample centrifuged 
(14000rpm, RT, 10 min).  After decanting the supernatant from the sample, more 
ethanol (70%, 250 µL) was added and the sample again centrifuged (14000rpm, RT, 
10 min).  The ethanol was carefully decanted and any remaining ethanol traces allowed 
to evaporate at RT overnight. 
6.2.7 Purification of DNA Using QIAGEN’s QIAquick® Gel Extraction Kit 
DNA fragments from endonuclease digests (§ 6.2.4) were excised from agarose gels (§ 
6.2.3) using a scalpel and purified using QIAGEN’s QIAquick® Gel Extraction kit 
according to the supplied protocol.  The procedure relies on the use of buffers, which 
selectively adsorb and elute DNA, at high and low salt concentrations respectively, to 
and from the silica membrane of the supplied column.   
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6.3 Mutagenesis Techniques 
6.3.1 Site Directed Mutagenesis 
Site directed mutagenesis was performed using Stratagene’s QuickChange® Site 
Directed Mutagenesis kit according to the supplied protocol.  PCR mixtures were set up 
as follows: 
 
 1 µL dsDNA template (50 ng µL-1) 
 3 µL Forward primer (40 ng µL-1) 
 3 µL Reverse primer (40 ng µL-1) 
 5 µL 10× Buffer  
 1 µL dNTP mix  
 37 µL Milli-Q H2O 
 
Pfu Turbo DNA polymerase (2.5U µL-1, 1 µL) was added and the reaction mixed with a 
pipette.  A PCR program of [95 ˚C, 30 s; 16× (95 ˚C, 30 s; 55 ˚C, 1 min; 68 ˚C, 13 min 
15 s); 4 ˚C, 5 min] was used. 
Dpn I (10U µL-1, 1 µL) was then added directly to the amplified reaction mixture, 
which was then mixed thoroughly using a pipette before incubating (37 ˚C, 1 h) in order 
to digest the parental DNA (i.e. methylated, non-mutated).  The degree of amplification 
was verified by agarose gel electrophoresis (§ 6.2.3) after the Dpn I digest. 
The resulting PCR mixture could then be transformed (§ 6.3.4 or § 6.3.5) directly.  
However, the success rate of transformation was greatly improved by prior purification 
of the DNA by ethanol precipitation (§ 6.2.6) and re-suspension of the DNA in Milli-Q 
H2O. 
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6.3.2 Random Mutagenesis - using a Mutator Strain (XL1-Red) 
Random mutagenesis was performed using the commercially available mutator strain, 
XL1-Red (Stratagene), with slight modification to the supplied protocol as follows.  
The supplied XL1-Red competent cells were thawed on ice and 100 µL aliquots 
pipetted into 14 mL Falcon polypropylene tubes.  1.42M β-mercaptoethanol (1.7 µL) 
was added to give a final concentration of 25 mM and the resulting mixture kept on ice 
for 10 min with occasional swirling. 
DNA (1 µL, 10-50 ng) was added and the mixture kept on ice for 30 min.  The tubes 
were then heat pulsed (42 ˚C, 45 s) in a water bath then placed back onto ice for 2 min.  
Pre-warmed (42 ˚C) SOC (900 µL) was added then the solution was incubated (37 ˚C, 
1 h, 250rpm). 
The inoculum was centrifuged (15000rpm, RT, 5 min) and the resulting cell pellet re–
suspended in SOC and plated onto LB agar plates containing appropriate antibiotic.  
The plates were then incubated (37 ˚C, 24 h). 
The colonies were washed off the agar plate using LB media to give a stock solution, 
which could be used to generate inoculated media.  Subsequent DNA isolation (§ 6.2.1) 
and transformation (§ 6.3.4 or § 6.3.5) into XL1-Blue allowed screening of the mutants 
as desired. 
 
6.3.3 Random Mutagenesis – using Error Prone PCR  
Error prone PCR (epPCR) was performed using Stratagene’s GeneMorph II Random 
Mutagenesis kit according to the supplied protocol.  PCR mixtures were set up as 
follows: 
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 1 µL DNA template (see Table 6.1 for amount) 
 0.5 µL Primer mix (250 ng µL-1 of each primer) 
 5 µL 10× Mutazyme II Reaction Buffer 
 1 µL 40 mM dNTP mix (200 µM each final) 
 1 µL Mutazyme II DNA polymerase (2.5U µL-1) 
 41.5 µL Milli-Q H2O 
 
Mutation rate Mutation 
frequency 
(mutations/ kb) 
Initial target 
amount (ng)* 
Recommended 
fold amplification 
Low 0-4.5 500-1000 1.5-10 
Medium 4.5-9 100-500 10-100 
High 9-16 0.1-100 100-10,000 
*Not the total amount of template to add but amount of target to amplify. 
Table 6.1 To show the quantity of DNA required for various mutation rates 
Components were mixed using a pipette before addition of the Mutazyme II DNA 
polymerase.  The mixture was centrifuged briefly before undergoing the following PCR 
program [95 ˚C, 2 min; 30× (95 ˚C, 1 min; 60 ˚C, 1 min; 72 ˚C, 1 min); 72 ˚C, 10 min; 
4 ˚C, 5 min]. 
The PCR product yield was quantified by comparison with the supplied 1.1-kb standard 
by agarose gel electrophoresis (§ 6.2.3). 
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6.3.4 Transformation – Heat Shock Method 
Transformation was carried out using XL1-Blue supercompetent cells (Stratagene) as 
follows. 
DNA (1 µL) was added to thawed XL1-Blue supercompetent cells (40 µL), mixed 
thoroughly with a pipette, then kept on ice for 30 min.  The tubes were then heat pulsed 
(42 ˚C, 45 s) in a water bath then placed back onto ice for 2 min.  Pre-warmed (37 ˚C) 
SOC (960 µL) was added then the tube was incubated (37 ˚C, 2 h, 250rpm). 
800 µL of the cell suspension was centrifuged (14000rpm, RT, 5 min) and the resulting 
cell pellet re-suspended in fresh, SOC media (50 µL) and streaked onto 2× YT agar 
plates supplemented with the appropriate antibiotic.  The plates were then incubated 
(37 ˚C, 18 h) to allow the transformed colonies to develop. 
 
6.3.5 Transformation - Electroporation Method 
Electrocompetent cells (40 µL) (§) were thawed on ice and 1.42 mM β-mercaptoethanol 
(0.68 µL) was added to a final concentration of 25 mM and the resulting mixture kept 
on ice for 10 min with occasional swirling. 
DNA (1 µL, 0.1-200 ng) was added and mixed using a pipette.  It was important that the 
DNA had a low ionic concentration to prevent arcing between the electrodes of the 
cuvette during the eletroporation process.  The mixture (50 µL) was added to a chilled 
cuvette (Gene Pulser®, 0.1 cm electrode gap, Bio-Rad) ensuring there were no air 
bubbles present.   
The cuvette was placed in the electroporation chamber (E. coli Pulser Electroporation 
apparatus, Bio-Rad) and subjected to a single pulse of 1.7 kV at a capacitance setting of 
25 µF and a resistance of 200 Ω.  These conditions correspond to a field strength of 
8.5 kV cm-1 with a time constant between 3.6 and 4.0 ms. 
The cells were then added to pre-warmed (37 ˚C) SOC (960 µL) then incubated (37 ˚C, 
2 h, 250rpm).  800 µL of the cell suspension was centrifuged (14000rpm, RT, 5 min) 
and the resulting cell pellet re-suspended in fresh, SOC media (50 µL) and streaked 
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onto 2× YT agar plates supplemented with the appropriate antibiotic.  The plates were 
incubated (37 ˚C, 18 h) to allow the transformed colonies to develop. 
 
6.3.6 Preparation of Competent Cells for Electroporation 
Glycerol freezes were thawed and streaked onto LB agar plates supplemented with the 
appropriate antibiotic. After incubation (37 ˚C, 24 h) a single colony was tooth picked 
into LB (5 mL) and incubated (37 ˚C, 24 h).  3 ml of the resulting cell culture was added 
to LB (250 mL) plus 0.1M MgSO4 (50 mL) and the resulting 1% inoculum incubated 
(37 ˚C, 180rpm) until the OD600 measured between 0.4 and 0.6 (approximately 3 h).  
The cell suspension was cooled on ice for 10 min then harvested by centrifugation 
(5500rpm, 4 ˚C, 5 min). 
The cell pellets were re-combined using ice cold TFB1 (100 mL) and the resulting 
suspension kept on ice for 10 min.  After centrifugation (5500rpm, 4 ˚C, 5 min) the cell 
pellets were re-combined using ice cold TFB2 (10 mL) and the resulting suspension 
kept on ice for 30 min.  Aliquots (200 µL) were snap frozen using a dry ice/acetone bath 
then stored immediately at -80 ˚C. 
 
6.4 Protein Preparation 
6.4.1 AT Protein Expression 
Glycerol freezes were thawed and streaked onto 2× YT agar plates supplemented with 
chloramphenicol (30 µg mL-1). After incubation (27 ˚C, 48 h) a single colony was tooth 
picked into 2× YT (5 mL) supplemented with chloramphenicol (30 µg mL-1) and 
incubated (27 ˚C, 24 h).  1 ml of the resulting cell culture was added to 2× YT (100 mL) 
supplemented with chloramphenicol (30 µg mL-1) and the resulting 1% inoculum 
incubated (27 ˚C 250rpm) until the OD600 measured >0.4 (usually 5 -6 hours).  The cells 
were induced with IPTG (0.1M, 300 µL) and incubated (27 ˚C, 16 h, 250rpm). 
The induced cells were harvested by centrifuging (5500rpm, 4 ˚C, 30 min).  The 
supernatant was discarded and the resulting cell pellet stored at -80 ˚C for at least 1 
hour, usually overnight, prior to lysis (§ 6.4.3, § 6.4.4 or § 6.4.5). 
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6.4.2 β  – Lactamase Protein Expression 
Glycerol freezes were thawed and streaked onto 2× YT agar plates supplemented with 
ampicillin (50 mg L-1). After incubation (37 ˚C, 16 h) a single colony was tooth picked 
into 2× YT (5 mL) supplemented with ampicillin (50 mg L-1) and incubated (27 ˚C, 
24 h).  1 ml of the resulting cell culture was added to 2× YT (100 mL) supplemented 
with ampicillin (50 mg L-1) and the resulting 1% inoculum incubated (37 ˚C, 16 h, 
250rpm). 
The cells were harvested by centrifuging (5500rpm, 4 ˚C, 30 min).  The supernatant was 
discarded and the resulting cell pellet stored at -80 ˚C for at least 1 hour, usually 
overnight, prior to lysis (§ 6.4.5). 
 
6.4.3 E. coli Cell Lysis – Sonication Method 
Cells underwent pulse sonication using a Sanyo MSE Soniprep 150 machine as follows. 
Cell pellets were thawed on ice, re-suspended in lysis buffer (5 mL) then kept on ice for 
1 hour.  The lysate then underwent pulse sonication, which consisted of 10 cycles of 
10 s at 10 µm amplitude followed by 20 s rest.  The lysate was kept on ice throughout 
sonication.  Protamine sulphate (5% w/v) was added and the resulting suspension 
centrifuged (5500rpm, 4 ˚C, 30 min).  The supernatant was transferred to a clean falcon 
tube and stored at -80 ˚C until required. 
 
6.4.4 E. coli Cell Lysis – BugBuster® Protein Extraction Reagent 
Cell lysis was performed using Novagen®’s BugBuster® Protein Extraction Reagent 
according to the supplied protocol as follows. 
The cell pellet was thawed on ice then re-suspended in the BugBuster® reagent 
(5 ml per g of cells).  The resulting solution was incubated (24 ˚C, 30 min, 100rpm), 
and then centrifuged (5500rpm, 4 ˚C, 30 min).  The supernatant was transferred to a 
clean falcon tube and stored at -80 ˚C. 
 
 126 
6.4.5 Fractionation of E. coli to obtain Periplasmic and Cytoplasmic Protein 
The cell pellets were thawed on ice and re-suspended in spheroplast buffer (10 mL per 
cell pellet from 50 mL culture).  The resulting solution was aliquoted (1.4 mL) and 
lysozyme (2 mg mL-1 stock solution) was added to a final concentration of 0.1 mg mL-1.  
The sample was inverted to mix then incubated (37 ˚C, 20 min).  After addition of 0.5M 
EDTA (30 µL), the sample was inverted to mix then centrifuged (13000rpm, RT, 90 s).  
750 µL from the top of the supernatant was removed to give the periplasmic fraction. 
The remainder of the supernatant was removed and the cell pellet re-suspended in TD 
buffer (1 mL).  The solution was centrifuged (13000rpm, RT, 2 min) and the resulting 
supernatant was the cytoplasmic fraction. 
 
6.4.6 Purification of MBP Fusions by Affinity Chromatography 
Ideally, protein purification is carried out in a cold room (4 ˚C).  However, the 
procedure was routinely carried out at RT, using ice-cold buffers and keeping all 
materials on ice throughout, with no apparent loss of yield or activity. 
The columns were prepared, as follows, using a 10 mL syringe with the plunger 
removed as the column.  Glass wool was used to plug the ‘column’, which was then 
packed with amylose resin (5 mL).  The resin was washed with column buffer (40 mL) 
to equilibriate the resin. 
The cell free extract was thawed on ice and column buffer (25 mL) added.  The 
resulting solution was applied to the column.  The eluted material was collected and 
applied to the column to ensure complete saturation of the resin.  The resin was washed 
with column buffer (40 mL) and the eluent monitored using Bradford reagent (10 µL 
eluent plus 100 µL Bradford reagent).  The eluent initially tests positive for protein 
however, towards the end of the wash protein should no longer be evident. 
The desired, maltose binding protein-protein fusion was eluted from the resin, using 
elution buffer (10 mL), and collected in fractions (1 mL).  The fractions were analysed 
with Bradford reagent and those containing protein were combined and aliquoted (200-
500 µL aliquots).  The protein aliquots were stored at -80 ˚C until required. 
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6.4.7 Quantification of Protein by Bradford Assay 
Proteins were quantified using the colorimetric Bradford Assay method (Bradford 
1976), as follows: 
Standard solutions (1 µg µL-1 to 0.25 µg µL-1) of bovine serum albumin (BSA) in 
column buffer were freshly prepared.  Each standard solution (10 µL) was added to 
Bradford reagent (1 mL) and the absorbance at 595 nm measured.  Column buffer was 
used as a blank.  A calibration plot was obtained. 
The protein sample solutions (10 µL) were also added to Bradford reagent (1 mL) and 
the absorbance at 595 nm measured.  The concentration of protein in the sample was 
determined by reference to the calibration plot. 
 
6.4.8 Analysis of Protein by SDS - PAGE 
Proteins were characterized using SDS-PAGE (Laemmli 1970) as follows.  
Electrophoresis was carried out in a Mini Protean II electrophoresis chamber (Bio-
Rad).(Laemmli 1970)(Laemmli 1970)(Laemmli 1970) 
Gels (0.75 mm) were cast according to the manufacturer’s (Bio-Rad) instructions as 
follows.  The cast was set up as described in the instructions.  Separating gel was 
prepared and immediately poured in to 1 cm below the bottom of the wells, using the 
comb as a guide.  The gel was covered with water-saturated iso-butanol and incubated 
(37 ˚C, 1 h).  The iso-butanol was carefully rinsed off the top of the gel using Milli-Q 
H2O or separating buffer and the comb was placed in the top of the cast.  The stacking 
gel was prepared and immediately poured into the cast until it reached the level of the 
top of the wells.  After incubation (37 ˚C, 1 h) the comb was removed and the wells 
were rinsed with Milli-Q H2O or running buffer.  The gel was then removed from the 
cast and placed into the electrophoresis tank.  1× SDS running buffer was poured into 
the tank, completely covering the gel, and the whole assembly placed in an ice bath.   
The samples (20 µL) were prepared by adding 1× SDS/DTT (10 µL).  The samples and 
protein marker were denatured (95 ˚C, 5 min) prior to loading into the wells of the gel.  
The samples (15 µL) and protein marker (15 µL) were loaded using a pipette with gel 
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saver tips.  1× SDS/DTT (15 µL) was added to any unused wells to ensure the gel ran 
evenly and without ‘smiling’.  
The tank was then connected to a power pack and a voltage applied to the gel. Gels 
were typically run at 20 mA for a single gel or 40 mA for two gels, until the 
bromophenol blue dye had reached the front of the gel, typically 90–120 min.  The 
power was then carefully switched off and the gel removed from the apparatus in 
preparation for staining. 
The gel was stained by covering with Coomassie Blue Stain solution and microwaving 
for 20 s followed by shaking (100rpm, RT, 2 min).  The Coomassie Blue Stain solution 
(reusable) was decanted off and the gel covered with Coomassie Blue destain solution, 
microwaved for 20 s then shaken (100rpm, RT, 2 min).  Staining and destaining was 
carried out twice.  Finally, the gel was covered with destain and left to shake overnight 
(100rpm, RT).  The destain was then poured off and the gel visualised using a UV 
Transilluminator - EPI light setting. 
 
6.5 Acylation Screening 
6.5.1 Amylose Affinity Membrane Screen Protocol 
The procedure used to screen AT mutant libraries for improved acylation activity was 
developed by previous group members, Cheung (2006) and Khara (2007) and was 
carried out as follows. 
The library glycerol stock was diluted and streaked onto 2× YT agar plates 
supplemented with chloramphenicol (30 µg mL-1) and IPTG (0.3 mM) and incubated 
(27 ˚C, 48 h).  The library was diluted to give approximately 1500 – 2000 colonies per 
22.5 × 22.5 cm plate. 
The colonies were then ‘lifted’ using an amylose affinity membrane (§ 6.5.2).  The 
membranes containing the bound colonies underwent a freeze-thaw cycle (-80 ˚C, 
30 min; 27 ˚C, 30 min), twice.  The membranes were then placed, cells facing upwards, 
on top of filter papers that had been pre-soaked in lysis buffer and sprayed with more 
lysis buffer.  After incubation (27 ˚C, 90 min), the membranes were washed by placing 
in column buffer (150 mL) and shaking (200rpm, RT, 30 min).  The membranes were 
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then dried, by placing on paper towels, before being placed, cells facing downwards, 
onto 2× YT agar plates containing ESS E. coli (§ 6.6.1).  
Depending on the solubility of the substrates being screened, they were either added to 
the ESS E. coli agar plates during their preparation, or, sprayed as an aqueous solution 
with a small amount of organic solvent (e.g. THF 5% v/v) on to the membranes once 
they had been placed on top of the ESS E. coli. agar plates.  Substrates were used at 
such concentrations that if acylation occurred the size of kill zone produced by an 
individual colony was large enough to visualise but not so large as to mask the effects 
of surrounding colonies. 
The ESS E. coli plate-membrane sandwich was then incubated (27 ˚C, 1 h) after which 
time the membranes were removed and the ESS E. coli agar plates incubated (37 ˚C, 
18 h).  The plates were checked by eye, for kill zones and the responsible colonies were 
selected from the original master plate for further investigation. 
 
6.5.2 Amylose Affinity Membrane Preparation 
The preparation of the membranes required for the acylation screening (§ 6.5.1) was 
based on work by Cattoli and Sarti (Cattoli and Sarti 2002). 
Cellulose matrix membranes (Whatman® 541 Hardened Ashless Cellulose filter paper 
24 cm diameter) (×50) were placed in an aqueous solution of sodium hydroxide (0.6M, 
1.1 L) containing sodium borohydride (2.2 g) and 1,4-diglycidyl ether (100%, 180 mL), 
and shaken (200rpm, RT, 8 h).  The filter papers were washed twice, by placing in 
Milli-Q H2O and shaking (200rpm, RT, 5 min), then placed in an aqueous solution of 
sodium hydroxide (0.6M, 320 mL) containing sodium borohydride (640 mg) and 
amylose solution (50 mg mL-1, 320 mL), and shaking (200rpm, RT, 18 h). 
The filter papers were washed by shaking (200rpm, RT, 10 min) in a solution of LDAO 
(0.1M, 1 L), and then placed in 2-ethanolamine (1M, 400 mL) and shaken, (200rpm, 
RT, 24 h). 
The filter papers were finally washed by placing alternately, in an aqueous solution of 
sodium chloride (1M, 800 mL) and shaking (200rpm, RT, 20 min) then, water (800 mL) 
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and shaking (200rpm, RT, 20 min), twice.  The filter papers were then dried on paper 
towels before being wrapped in foil and sterilised by autoclaving at 121 ˚C for 20 min. 
The resulting membranes were stored at 4 ˚C and sterilised by UV irradiation before 
use. 
 
6.6 AT Mutant Activity Determination 
Kinetic studies were routinely carried out, in triplicate, in order to compare the activity 
of newly identified mutants with wild type AT and other mutants.  Due to the 
comparative nature, it was essential that all the proteins used in any one kinetic study 
were expressed and purified together, as a batch, using the same reagents and buffers to 
ensure the test was, as far as possible, fair. 
Generally, reactions were set up containing a β-lactam nucleus and acyl donor plus AT 
and the reactions incubated.  Samples were taken at various time points and were 
quenched by the addition of ice-cold methanol.  Substrate concentrations were such that 
upon addition of samples to a bioplate, measurable kill zones would be obtained. 
 
6.6.1 ESS E. coli Bioplate Preparation 
ESS E. coli was kindly provided by DSM, Delft, The Netherlands.  Single colonies of 
ESS E. coli were tooth picked into 2× YT (5 mL) and incubated (37 ˚C, 18 h, 250rpm).  
The resulting cell culture was diluted using glycerol:Milli-Q H2O in a 1:1 ratio, then 
aliquoted (300 µL).  The resulting glycerol stocks were stored at -80 ˚C until required. 
ESS E. coli glycerol stock (300 µL) was added to 2× YT (100 mL) and incubated 
(27 ˚C, 250rpm) until the OD600 absorbance measured 2.0 (approximately 12 h).  The 
cell culture was then diluted ten-fold using freshly prepared 2× YT agar at T<42 ˚C to 
give a final OD600 absorbance of 0.2.  The mixture was then poured into Petri dishes 
(18 mL per round Petri dish (90 mm), or 70 mL per square Petri dish (22.5 × 22.5 cm)).  
The plates were allowed to cool at RT for 30 min.  The plates were stored at 4 ˚C and 
used within two days.  Prior to use the plates were allowed to equilibriate at RT for 
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30 min then a cork borer was used to make wells (7 mm diameter) in the plates 
immediately before use. 
 
6.6.2 Calibration of ESS E. coli Bio Plates 
Each batch of ESS E. coli bio plates was calibrated with respect to AdiPen [26] as 
follows. 
A range of AdiPen [26] standards, (3.2 – 64 nM in 40 µL) were prepared by serial 
dilution of a stock solution (1.6 mM) using HEPES buffer and were pipetted into the 
wells of bioplates.  Any plate-to-plate variations were accounted for by placing 
duplicate aliquots on different plates.  The plates were then incubated (37 ˚C, 18 h) and 
the resulting kill zones measured in mm.  Kill zones were the diameter of the clear ring 
around the well minus the diameter of the well and correspond to growth inhibition due 
to diffusion of the antibiotic into the agar.  Calibration curves could then be plotted 
from the resulting data. 
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6.6.3 Bioplate Assay (Fleming 1989) 
6-APA [1] (1.6 mM, 100 µL), AdiCoA [32] or AdiNAC [33] (5 mM, 100 µL) were 
mixed together and pre-warmed by placing in a heating block (26˚C, 5 min).  A solution 
of the enzyme, made up to 200 µL in HEPES buffer (50 mM, pH 7.4) with DTT (5 mM) 
was then added.  The resulting mixture was mixed using a pipette.  Aliquots (40 µL) 
were taken every 10 min.  The aliquots were quenched by adding to ice-cold methanol 
(40 µL), vortexing then placing on ice.  The aliquot (80 µL) was added to the well of a 
bioplate, which was then incubated (37˚C, 18 h).  The kill zones were measured in mm 
and the amount of conversion determined by reference to the calibration curves (§ 
6.6.2). 
 
6.7 Synthesis of Substrates 
6.7.1 Preparation of S-Adipoyl-N-Acetyl-Cysteamine (AdiNAC) [33] 
 
Under anhydrous conditions, N-acetylcysteamine (1.78 mL, 16.8 mM) and triethylamine 
(2.34 mL, 16.8 mM) in THF (50 mL) were added drop wise over 30 minutes to a 
solution of adipoyl chloride (2.44 mL, 16.8 mM) in THF (50 mL) then left to stir at 
room temperature for 1 hour.  The resulting suspension was filtered by suction to 
remove the precipitated Et3N·HCl salt, and the solution concentrated in vacuo to give an 
amber oil.  This oil was dissolved in H2O and extracted with EtOAc (2 × 50 mL).  The 
organic extracts were combined and the volume reduced by half in vacuo.  A saturated 
solution of sodium bicarbonate was added until the pH was 5.5 and the organic layer 
was back-extracted with H2O (2 × 50 mL).  The aqueous extracts were combined and 
the H2O removed by lyophilisation to give the title compound as a white solid (1.67 g, 
38%). 
m.p. 235-237˚C; vmax (film)/cm-1 3292m (NH), 1692s (COOH), 1640s (NHCO), 1562s 
(SCO); δH (CDCl3, 300 MHz) 1.39-1.57 (4H, m, CH2CH2CH2CO), 1.82 (3H, s, CH3), 
2.09 (2H, t, J 7.57, CH2CO2H), 2.56 (2H, t, J 6.94, SCOCH2), 2.95 (2H, t, J 6.15, 
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SCH2), 3.26 (2H, t, J 6.30, HNCH2); m/z (Cl+) 248 (M-H 20%), calculated for 
C10H17O4NS = 246.0878. 
 
6.7.2 Preparation of Adipoyl Coenzyme A (AdiCoA) [32] 
 
Coenzyme A sodium salt (100 mg, 1.3×10-4 mol) was suspended in a mixture of acetone 
(15 mL) and H2O (150 µL).  The mixture was cooled by placing in an ice-bath and the 
pH adjusted to 8 using 0.2 M NaHCO3.  Adipoyl chloride (37.98 µL, 2.6 × 10-4 mol) 
was added slowly dropwise to the stirring solution.  After one hour of stirring on ice and 
careful maintenance of the pH, the reaction was concentrated in vacuo then lyophilised 
to give the title compound as a white solid (113.4 mg, 95%). 
δH (D2O, 500 MHz) 0.59 (3H, s, CH3CCH3), 0.74 (3H, s, CH3CCH3), 1.36-1.54 (4H, m, 
CH2CH2CH2CO), 2.08 (2H, t, J 6.78, NHCOCH2CH2), 2.30 (2H, t, J 6.47, CH2CO2H), 
2.34 (2H, t, J 6.62, SCOCH2), 2.62 (2H, t, J 6.31, SCH2CH2NH), 3.19 (2H, t, J 6.47, 
SCH2CH2NH/COCH2CH2NH), 3.31 (2H, t, J 5.05 SCH2CH2NH/COCH2CH2NH), 3.38-
3.46 (1H, m, OCHCHOPO3-/OCHCHOH), 3.67-3.74 (1H, m, OCHCHOPO3-
/OCHCHOH), 3.87 (1H, s, COCHOH), 4.10 (2H, s, (CH3)2CCH2), 4.46 (1H, s, 
OCHCHOPO3-), 6.05 (1H, d, J 6.94, OCHCHOH), 8.13 (1H, s, NCHN/ NH2CNCH), 
8.41 (1H, s, NCHN/NH2CNCH) 
m/z (ES-) 894.2 (M-H 4.7%), 187.4 (100%), 218.4 (64%), calculated for 
C27H44O19N7SP3 = 895.6615. 
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Appendix B pHAR4-p Plasmid Map 
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Appendix C pUC18 Plasmid Map 
 
 
 
 
 145 
Appendix D Oligonucleotide Sequences 
 
 
 
Chapter 2 pHAR10a plasmid (6623bp) penDE (3005-4075) 
Sequencing Primers 
  2901         2921 
S0  5´-TTA GCT CAC TCA TTA GGC ACC-3´ 
  2998                3024 
S1  5´-AGA CCA TAT GCT TCA CAT CCT CTG TCA-3´ 
  3251         3271 
S2  5´-ATT GTC ATG CTT AAT ACC CGC-3´ 
  3271           3251 
AS2  5´-GCG GGT ATT AAG CAT GAC AAT-3´ 
  3311         3331 
S3  5´-TGC ACC ACT GCC TAT TGT CAA-3´ 
  3331          3311 
AS3  5´-TTG ACA ATA GGC AGT GGT GCA-3´ 
  3377           3397 
S4  5´-GCC ACC AAA GAG AAC CTG ATC-3´ 
  3397          3377 
AS4  5´-GAT CAG GTT CTC TTT GGT GGC-3´  
  3470           3490 
S5  5´-GGA TTT AAC AGT GCG GGG GTC-3´ 
  3490          3470 
AS5  5´-GAC CCC CGC ACT GTT AAA TCC-3´ 
  3521          3541 
S6  5´-GGT CTT CGA CCC ACC GGA GTT-3´ 
  3541           3521 
 146 
AS6  5´-AAC TCC GGT GGG TCG AAG ACC-3´ 
  3752           3772 
S7  5´-CTT CAG CAC GGC AAA AAT GAG-3´ 
  3772         3752 
AS7  5´-CTC ATT TTT GCG GTG CTG AAG-3´ 
  4070         4090 
S8  5´-AGG CTT TCT AGA TCG AGC TCG -3´ 
  4090          4070 
AS8  5´-CGA GCT CGA TCT AGA AAG GCT-3´ 
  4136        4126 
AS9  5´-CTT CGA TTT TGG ATC CGT TGT-3´ 
 
Site Directed Mutagenesis Primers 
Arg70Leu 
  3197              3229 
S  5´-TAC TAC GAG GAG ATT CTC GGT ATT GCA AAG GGC-3´ 
  3229             3197 
AS  5´-GCC CTT TGC AAT ACC GAG AAT CTC CTC GTA GTA-3´ 
 
Asn267Ser 
  3788              3820 
S  5´-TTA CCG GAC TCA TGG AGT CGC CAC CAG CGT ATG-3´ 
  3820              3788 
AS  5´-CAT ACG CTG GTG GCG ACT CCA TGA GTC CGG TAA-3´ 
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Chapter 4 pHAR4-p plasmid (8594bp) penDE (2761-3834) 
Sequencing Primers 
As for pHAR10a (primers S2, AS2, S3, AS3, S4, AS4, S5, AS5, S6, AS6, S7, AS7) 
plus the following; 
  2051          2071 
 per1S  5´-TCA ACC TGC AAG AAC CGT ACT-3´ 
  2701          2721 
per2S  5´-ACT AAT TCG AGC TCG AAC AAC-3´ 
  2721         2701 
per2AS 5´-GTT GTT CGA GCT CGA ATT AGT-3´ 
  4021           4000 
per3AS 5´-TTG GGA AGG GCG ATC GGT GCG-3´ 
 
Site Directed Mutagenesis Primers 
Arg1Met 
  2746             2779 
S  5´-CTC GGG ATC GAG GGA ATG CTT CAC ATC CTC TGT-3´ 
  2779              2746 
AS  5´-ACA GAG GAT GTG AAG CAT TCC CTC GAT CCC GAG-3´ 
 
Glu338Ser 
  3757             3780 
S  5´-CGG ACC AAC CCT GAT TCG ATG TTT GTC ATG CGG-3´ 
  3780              3757 
AS  5´-CCG CAT GAC AAA CAT CGA ATC AGG GTT GGT CGG-3´ 
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Chapter 5 pUC18 plasmid (2686bp) bla (201-1061) 
Sequencing Primers 
  96        116 
blaS1  5´-CGC GGA ACC CCT ATT TGT TTA-3´ 
  1127         1107 
blaAS2 5´-CCT TTT AAA TTA AAA ATG AAG-3´ 
  281           301 
blaS3  5´-GCT GGT GAA AGT AAA AGA TGC-3´ 
  2170         2151 
blaAS4 5´-ATA CGA GCC GGA AGC ATA AAC-3´ 
 
Site Saturation Mutagenesis Primers 
 
Asn132Xxx 
  573              605 
S  5´-ATA ACC ATG AGT GAT NNN ACT GCG GCC AAC TTA-3´ 
  605              573 
AS  5´-TAA GTT GGC CGC AGT NNN ATC ACT CAT GGT TAT-3´ 
 
Ala237Xxx 
  888               920 
S  5´-GCT GAT AAA TCT GGA NNN GGT GAG CGT GGG TCT-3´ 
  920              888 
AS  5´-AGA CCC ACG CTC ACC NNN TCC AGA TTT ATC AGC-3´ 
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Site Directed Mutagenesis Primers 
 
Asn132Asp 
  573              605 
S  5´-ATA ACC ATG AGT GAT GAC ACT GCG GCC AAC TTA-3´ 
  605              573 
AS  5´-TAA GTT GGC CGC AGT GTC ATC ACT CAT GGT TAT-3´ 
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Appendix E P. chrysogenum vs A. nidulans 
 
 
 
Comparison of amino acid sequences of the penDE genes from Penicillin chrysogenum 
and Aspergillus nidulans (Cheung 2006).  Only the mismatches are shown for 
Aspergillus nidulans. 
                             1                    10                     20                    30                       40 
P. chrysogenum   MLHILCQGTPEEIGYEHGSAAKAVIARSIDFAVDLIRGKT 
A. nidulans                VT             S         H                GE     KA                   
                           41                     50                    60                    70                       80 
P. chrysogenum   KKTDEELKQVSQLGRVIEERWPKYYEEIRGIAKGAERDV 
A. nidulans                QA     E   L   RE            MKQ     R            C                     E 
                           81                   90                      100                     110                       120 
P. chrysogenum   SEIVMLNTRTEFAYGLKAARDGCTTAYCQLPNGALQGQNW 
A. nidulans                                                    VE                   V      KT  
                          121                  130                 140                  150                  160 
P. chrysogenum   DFFSATKENLIRLTIRQAGLPTIKFITEAGIIGKVGFNSA 
A. nidulans                  T                 Q      C   P           M         
                          161                     170                   180                  190                   200 
P. chrysogenum   GVAVNYNALHLQGLRPTGVPSHIALRIALESTSPSQAYDR 
A. nidulans                                         H                 L      L       M                  E      EK    
                          201                   210                     220                  230                      240 
P. chrysogenum   IVEQGGMAASAFIMVGNGHEAFGLEFSPTSIRKQVLDANG 
A. nidulans               S                                       A        Y               I    LC      A  T     
                          241                  250                       260                     270                    280 
P. chrysogenum   RMVHTNHCLLQHGKNEKELDPLPDSWNRHQRMEFLLDGFD 
A. nidulans               I                      N      PSAQ      N                S      G        H     S          
                          281                   290                    300                   310                   320 
P. chrysogenum  GTKQAFAQLWADEDNYPFSICRAYEEGKSRGATLFNIIYD 
A. nidulans                  E        K       E                L               K               S            VF 
                          321                   330                    340                     350             357       
P. chrysogenum   HARREATVRLGRPTNPDEMFVMRFDEEDERSALNARL 
A. nidulans             VG   K                    N           T          T  SNL   TK     IQ    NI  
 151 
Appendix F  E. coli Strains 
 
 
 
XL1-Blue 
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F’ proAB laclqZDM15Tn10 
(Tetr)]. 
 
XL1-Red 
endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac mutD5 mutS mutT Tn10 (Tetr) 
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Appendix G 1H NMR Spectra for Chapter 4 
